Journal of Clinical Psychiatry

Subject Index to Volume 62: January 2001 Through December 2001

Academic Highlights
Trauma and stress: diagnosis and treatment [CME]. Nov 906–915
Understanding depression: a long-term, recurring disorder. May 379–392
Acamprosate
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Mason BJ. Suppl 20. 42–48
ADHD
Effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. Kooij. Dec 952–956
Adolescents
Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. Chen NC. June 479–480
Neuroleptic-related dyskinesias in children and adolescents [CME]. Connor DF. Dec 967–974
Preliminary survey of rhinotillexomania in an adolescent sample. Andrade. June 426–431
Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. Grant. July 517–522
Randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Buitelaar. Apr 239–248
Affective Disorders
Suicidality and substance abuse in affective disorders. Goldberg. Suppl 25. 35–43
Aggression
Chronic assaultive behavior improved with sleep apnea treatment [letter]. Dennis. July 571–572
Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. Chen NC. June 479–480
Randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Buitelaar. Apr 239–248
Agitation
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon. Suppl 2. 17–21
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Lesem. Jan 12–18; Correction. Mar 209
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Currier. Mar 153–157
Akathisia
Remission of SSRI-induced akathisia after switch to nefazodone [letter]. Chelben. July 570–571
Alcohol
Alcohol abuse and alcoholism: an overview. Volpicelli. Suppl 20. 4–10
Comorbid alcoholism and depression: treatment issues. Thase. Suppl 20. 32–41
Introduction: pharmacologic treatment of alcohol abuse and addiction. O'Brien CP. Suppl 20. 3
Pharmacologic approaches to the management of alcoholism. Anton. Suppl 20. 11–17
Role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Naranjo. Suppl 20. 18–25
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Mason BJ. Suppl 20. 42–48
Use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. Pettinati. Suppl 20. 26–31
Algorithm, Treatment
Algorithm for the treatment of chronic depression. Trivedi. Suppl 6. 22–29
Using treatment algorithms for the effective management of treatment-resistant depression. Trivedi. Suppl 18. 25–29
Alzheimer's Disease see also Dementia
Effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Clark. Jan 34–40
Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. Ballard. Jan 46–49
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. Mintzer. Suppl 21. 23–25
Anticholinergics
Cost savings with intramuscular anticholinergics [letter]. Markowitz. Apr 295
Anticonvulsants
Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). Jefferson. Suppl 1. 50–53
Cognitive side effects of anticonvulsants. Goldberg. Suppl 14. 27–33
Cutaneous reactions to anticonvulsant medications. Hebert. Suppl 14. 22–26
Introduction: role of anticonvulsants as mood stabilizers. Bowden. Suppl 14. 3–4
Major system toxicities and side effects of anticonvulsants. Swann AC. Suppl 14. 16–21
Antidepressants see also specific drugs
Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Preda. Jan 30–33
Antidepressant treatment and global tests of coagulation and fibrinolysis [letter]. Lederbogen. Feb 130
Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. Parker. Feb 117–125
Characterizing the ideal antidepressant therapy to achieve remission. Ferrier. Suppl 26. 10–15
Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. Demyttenaere. Suppl 22. 30–33
Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. Demyttenaere. Suppl 22. 34–37
Debate and discussion: do some antidepressants have a faster onset of action than others? Suppl 4. 37–40
Do some antidepressants work faster than others? Nierenberg. Suppl 15. 22–25
Early onset of antidepressant action: impact on primary care. Culpepper. Suppl 4. 4–6
Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. Ghaemi. July 565–569
Effects of antidepressants on sexual functioning in depressed patients: a review. Ferguson. Suppl 3. 22–34
Evidence of early onset of antidepressant effect in randomized controlled trials. Stahl. Suppl 4. 17–23
Ideal trial to test differential onset of antidepressant effect. Leon. Suppl 4. 34–36
Impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. Altshuler L. Aug 612–616
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Montejo. Suppl 3. 10–21
Introduction: early onset of antidepressant action. Rosenbaum. Suppl 4. 3
Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. Leon. Suppl 4. 12–16
Methodology to measure onset of action. Thase. Suppl 15. 18–21
Pharmacology of rapid-onset antidepressant treatment strategies. Blier. Suppl 15. 12–17
Possible neurobiological mechanisms underlying faster onset of antidepressant action. Blier. Suppl 4. 7–11
Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. Frazer. Suppl 12. 16–23
Should we keep calling antidepressants *antidepressants*? [letter] Lara; Schatzberg reply. Oct 829–830

Strategies for the treatment of antidepressant-related sexual dysfunction. Zajecka. Suppl 3, 35–43
Suicide in primary affective disorders revisited: a systematic review by treatment era [CME]. O'Leary. Oct 804–811
Switching antidepressants for treatment-resistant major depression. Marangell. Suppl 18, 13–17
Treatment of social phobia with antidepressants. Schneier. Suppl 1, 43–48
Type II error and antidepressants [letter]. Walker JB; Weihs reply. May 373–375
Antimanic Agents
Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. Grunze. June 464–468
Development of study exit criteria for evaluating antimanic compounds. Frank. June 421–425
Antipsychotics see also specific drugs
Adherence assessments and the use of depot antipsychotics in patients with schizophrenia [CME]. Valenstein. July 545–551
Adverse effects of atypical antipsychotics. Wirshing DA. Suppl 21, 7–10
Antipsychotic-associated weight gain and clinical outcome parameters. Blin. Suppl 7, 11–21
Antipsychotic-induced weight gain: a review of the literature. Allison. Suppl 7, 22–31
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Czekalla. Suppl 2, 35–40
Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. Henderson DC. Suppl 27, 10–14
Clinical implications of weight gain in schizophrenia. Kurzthaler. Suppl 7, 32–37
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania [CME]. Miller DS. Dec 975–980
Comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Malla. Mar 179–184
Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Aizenberg. July 541–544
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 2: illustrating their mechanism of action [BRAINSTORMS]. Stahl. Dec 923–924
Effects of atypical antipsychotics on weight and serum lipid levels. Meyer JM. Suppl 27, 27–34
Genetic dissection of atypical antipsychotic–induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile. Suppl 23, 45–66
"Hit-and-run" actions at dopamine receptors, pt 1: mechanism of action of atypical antipsychotics [BRAINSTORMS]. Stahl. Sept 670–671
"Hit-and-run" actions at dopamine receptors, pt 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics [BRAINSTORMS]. Stahl. Oct 747–748
Hyperglycemia and antipsychotic medications. Haupt. Suppl 27, 15–26
Hyperglycemia associated with the use of atypical antipsychotics. Lindenmayer. Suppl 23, 30–38
Hypothermia in 2 patients treated with atypical antipsychotic medication [letter]. Parris. Jan 61–63
Hypothesis and hypothesis testing in the clinical trial. Lieberman. Suppl 9, 5–8
Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? [CME] Bloch. Nov 855–859
Interpretations and conclusions in the clinical trial. Docherty. Suppl 9, 40–43
Introduction: metabolic disturbances associated with antipsychotic use. Newcomer. Suppl 27, 3–4
Introduction. Weight gain: a growing problem in schizophrenia management. Meltzer. Suppl 7, 3
Introduction: weight gain and glucose regulation during antipsychotic drug treatment. Sussman. Suppl 23, 3–4
Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. Hägg. Nov 843–848
Mechanisms of antipsychotic-induced weight gain. McIntyre. Suppl 23, 23–29
Metabolic Disturbances Associated With Antipsychotic Use. Suppl 27, 1–44
Metformin in obesity associated with antipsychotic drug administration: a pilot study [letter]. Baptista. Aug 653–655
Movement disorders associated with neuroleptic treatment. Wirshing WC. Suppl 21, 15–18
Neuroleptic-related dyskinesias in children and adolescents [CME]. Connor DF. Dec 967–974
Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. Cutler. Suppl 5, 10–13
Pharmacology of weight gain with antipsychotics. Casey. Suppl 7, 4–10
Priapism associated with conventional and atypical antipsychotic medications: a review. Compton. May 362–366
Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. Meltzer. Suppl 27, 35–39
Review of atypical antipsychotics and weight gain. Sussman. Suppl 23, 5–12
Service use and costs of treating schizophrenia with atypical antipsychotics. Lewis M. Oct 749–756
Statistical comparison of clinical trials. Schooler. Suppl 9, 35–37
Weight change and atypical antipsychotic treatment in patients with schizophrenia. Jones B. Suppl 2, 41–44
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. Simpson MM. Sept 694–700
Antiretroviral Agents
Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia. Walkup. Mar 174–178
Anxiety see also specific disorders
Anxiety disorders following miscarriage. Geller. June 432–438
Biological differences in depression and anxiety across races and ethnic groups. Lin. Suppl 13, 13–19
Burden of depression and anxiety in general medicine. Lecrubier. Suppl 8, 4–9
Consensus statement on depression, anxiety, and cardiovascular disease. Ballenger. Suppl 8, 24–27
Consensus statement on depression, anxiety, and functional gastrointestinal disorders. Ballenger. Suppl 8, 48–51
Consensus statement on depression, anxiety, and oncology. Ballenger. Suppl 8, 64–67
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. Ballenger. Suppl 13, 47–55
Contemporary management of comorbid anxiety and depression in geriatric patients. Doraiswamy. Suppl 12, 30–35
Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. Kirmayer. Suppl 13, 22–28
Depression and anxiety in oncology: the oncologist's perspective. Jones RD. Suppl 8, 52–55
Depression and anxiety in oncology: the psychiatrist's perspective. Berard. Suppl 8, 58–61
Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. Sheps. Suppl 8, 12–16
Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. Roose. Suppl 8, 19–22
Depression, anxiety, and the gastrointestinal system. Mayer. Suppl 8, 28–36
Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Trivedi. Oct 776–781
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH. July 523–529
Epidemiology, burden, and disability in depression and anxiety. Lépine. Suppl 13, 4–10
Familial psychiatric illness and posttraumatic stress disorder: findings from a family study of substance abuse and anxiety disorders [CME]. Dierker. Sept 715–720
Introduction: focus on depression and anxiety disorders in general medicine. Suppl 8, 3
Introduction: focus on transcultural issues in depression and anxiety. Ballenger. Suppl 13, 3
Introduction: remission of anxiety-related disorders. Shelton RC. Suppl 12, 3–4
Irritable bowel syndrome, anxiety, and depression: what are the links? Lydiard. Suppl 8, 38–45
Mechanisms of action in the treatment of anxiety. Shelton RC. Suppl 12, 10–15
Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Tajima. Suppl 13, 39–44
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Pollack. May 350–357; Correction. Aug 658
Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown Anxiety Disorders Research Program. Salzman. Mar 149–152
Prescribing patterns for depression and anxiety worldwide. Lecrubier. Suppl 13, 31–36
Prevalence, recognition, and treatment of comorbid depression and anxiety. Rapaport. Suppl 24, 6–10
Treatment of anxiety disorders to remission. Ballenger. Suppl 12, 5–9
Assessment
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and

psychological symptoms of dementia. De Deyn, Suppl 21, 19–22

AT_1 Blockers

Lithium intoxication after administration of AT_1 blockers [letter]. Zwanzger, Mar 208–209

Augmentation

Addition of risperidone to clozapine therapy in chronically psychotic inpatients [letter]. de Groot, Feb 129–130

Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients [CME]. Posternak, Feb 135–142

Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. Agid, Mar 169

Autism

Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. Chen NC, June 479–480

Open trial of divalproex sodium in autism spectrum disorders. Hollander, July 530–534

Behavioral Therapy

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy [CME]. Alonso, July 535–540

Benzodiazepines

Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). Jefferson, Suppl 1, 50–53

Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder [letter]. Arató, Aug 657–658

Bereavement

Bupropion sustained release for bereavement: results of an open trial. Zisook, Apr 227–230

Bioequivalence

Branded versus generic clozapine: bioavailability comparison and interchangeability issues. Lam YWF, Suppl 5, 18–22

Conclusion: comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky, Suppl 5, 27–27

Introduction: comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky, Suppl 5, 3

United States Food and Drug Administration requirements for approval of generic drug products. Meyer, Suppl 5, 4–9

Bipolar Disorder

Antidepressant-induced mania in bipolar patients: identification of risk factors. Henry, Apr 249–255

Bipolar affective disorder and idiopathic pulmonary fibrosis [letter]. Bhandari, July 574–575

Bipolar rapid cycling: focus on depression as its hallmark. Calabrese, Suppl 14, 34–41

Bipolar spectrum disorder: improving its recognition and diagnosis. Hirschfeld, Suppl 14, 5–9

Citalopram as adjunctive therapy in bipolar depression. Kupfer, Dec 985–990

Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. Fava GA, July 556–559

Determinants of overweight and obesity in patients with bipolar disorder [CME]. Elmslie, June 486–491

Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. Wozniak, Suppl 14, 10–15

Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. Kaplan, Dec 936–944

Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. Ghaemi, July 565–569

Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. Ciapparelli, July 552–555

Family member's legal experience with an insurer's refusal to recertify inpatient mental health treatment. Shyovitz, Suppl 25, 44–50

High prevalence of bipolar spectrum disorders [letter]. Benazzi; Ghaemi reply, Sept 735–736

Identifying and managing suicide risk in bipolar patients. Oquendo, Suppl 25, 31–34

Impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. Altshuler L, Aug 612–616

Integration of suicide prevention into outpatient management of bipolar disorder. Sachs, Suppl 25, 3–11

Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Sanger, Apr 273–281

Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. Gray, Suppl 25, 56–64

Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Vieta, Oct 818–825

Smoking habits in bipolar and schizophrenic outpatients in southern Israel. Itkin, Apr 269–272

Suicide attempts in bipolar patients. López, Dec 963–966

Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. Suppes, June 439–447

Topiramate abuse in a bipolar patient with an eating disorder [letter]. Colom, June 475–476

Bleeding

Antidepressant treatment and global tests of coagulation and fibrinolysis [letter]. Lederbogen, Feb 130

Body Dysmorphic Disorder

Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. Phillips KA, Feb 87–91

Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. Phillips KA, Sept 721–727

Fatal body dysmorphic disorder by proxy [letter]. Atiullah, Mar 204–205

Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. Grant, July 517–522

Retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder [CME]. Saxena, Jan 67–72

Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report [letter]. Grant, Apr 297–298

Books Reviewed

American Psychiatric Association: *Psychiatric Services in Jails and Prisons: A Task Force Report of the American Psychiatric Association, 2nd ed.* Bernet, Aug 662

Andrews G, Henderson S (eds): *Unmet Need in Psychiatry: Problems, Resources, Responses.* Ronis, Feb 132–133

Appleton WS: *Prozac and the New Antidepressants, revised ed.: What You Need to Know About Prozac, Zoloft, Paxil, Luvox, Wellbutrin, Effexor, Serzone, Vestra, Celexa, St. John's Wort, and Others.* Ebert, Mar 210

Bennett MJ: *The Empathic Healer: An Endangered Species?* Salzman, Oct 831–832

Bloom JD, Nadelson CC, Notman MT (eds): *Physician Sexual Misconduct.* Lomax, Sept 738

Bradley SJ: *Affect Regulation and the Development of Psychopathology.* Harmon, June 481

Cepeda C: *Concise Guide to the Psychiatric Interview of Children and Adolescents.* Brooks, Feb 131

Cloninger CR (ed): *Personality and Psychopathology.* Alarcón, Apr 300–301

Coffey CE, Cummings JL (eds): *The American Psychiatric Press Textbook of Geriatric Neuropsychiatry, 2nd ed.* Rabins, July 577

Coles R (ed): *The Erik Erikson Reader.* Wells, July 576

Davidson JRT, Connor KM: *Herbs for the Mind: What Science Tells Us About Nature's Remedies for Depression, Stress, Memory Loss, and Insomnia.* Lamps, Sept 738–739

Evans RW, Mathew NT: *Handbook of Headache.* Lavin, Aug 660–661

Foa EB, Keane TM, Friedman MJ (eds): *Effective Treatments for PTSD: Practice Guidelines From the International Society for Traumatic Stress Studies.* Freeman, Nov 905

Fogel BS, Schiffer RB, Rao SM (eds): *Synopsis of Neuropsychiatry.* Salzman, Feb 131–132

Frank E (ed): *Gender and Its Effects on Psychopathology.* Freeman, June 481–482

Gabbard GO: *Psychodynamic Psychiatry in Clinical Practice, 3rd ed.* Nash, Apr 302

George MS, Belmaker RH (eds): *Transcranial Magnetic Stimulation in Neuropsychiatry.* Regan, Mar 210

Iversen LL: *The Science of Marijuana.* Salzman, Aug 661–662

Kennedy GJ: *Geriatric Mental Health Care: A Treatment Guide for Health Professionals.* Salzman, Sept 737–738

Klein RH, Schermer VL (eds): *Group Psychotherapy for Psychological Trauma.* Roback, May 377–378

Kushner HI: *A Cursing Brain? The Histories of Tourette Syndrome.* Findling, July 578

Lauterbach EC (ed): *Psychiatric Management in Neurological Disease, 1st ed.* Slaughter, June 483–484

Lock J, Le Grange D, Agras WS, Dare C: *Treatment Manual for Anorexia Nervosa: A Family-Based Approach.* Bowers, Oct 831

Mallick BN, Inoué S (eds): *Rapid Eye Movement Sleep.* Solomon RM, May 378

Manji HK, Bowden CL, Belmaker RH (eds):

Bipolar Medications: Mechanisms of Action. Reus. July 576–577
Meeks JE, Bernet W. *The Fragile Alliance: An Orientation to Psychotherapy of the Adolescent, 5th ed.* Brooks. June 482–483
Mitchell JE: *Points of View: Stories of Psychopathology.* Racy. Dec 997
Mitchell JE, Crosby RD, Wonderlich SA, Adson DE: *Elements of Clinical Research in Psychiatry.* Schwab. Aug 659
Okasha A, Arboleda-Flórez J, Sartorius N (eds): *Ethics, Culture, and Society: International Perspectives.* Nelson SH. Aug 661
Piasecki M, Newhouse PA (eds). *Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics.* Weinstein. June 483
Raphael B, Wilson JP (eds): *Psychological Debriefing: Theory, Practice and Evidence.* Risby. Dec 996
Rapoport JL (ed): *Childhood Onset of "Adult" Psychopathology: Clinical and Research Advances.* Findling. Feb 132
Reveley MA, Deakin JFW (eds): *The Psychopharmacology of Schizophrenia.* Rubin. July 577
Ron MA, David AS (eds): *Disorders of Brain and Mind.* Risby. May 377
Rudd MD, Joiner T, Rajab MH: *Treating Suicidal Behavior: An Effective, Time-Limited Approach.* Crowder. Dec 996–997
Salzman C: *Psychiatric Medication for Older Adults: The Concise Guide.* Jones BN. Sept 739
Sameroff AJ, Lewis M, Miller SM (eds): *Handbook of Developmental Psychopathology, 2nd ed.* Pfeffer. Oct 832–833
Shorto R, Holt H: *Saints and Madmen: Psychiatry Opens Its Doors to Religion.* Gay. Apr 301–302
Tomb DA: *Psychiatry (House Officer Series, 6th ed.)* Lamps. Jan 64–65
Wall PD, Melzack R (eds): *Textbook of Pain, 4th ed.* Streltzer. Aug 660
Wear-Finkle DJ: *Medicolegal Issues in Clinical Practice: A Primer for the Legally Challenged.* Caruso. Aug 659–660
Weiden PJ, Scheifler PL, Diamond RJ, Ross R: *Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians.* Salomon RM. Jan 65
Weissman S, Sabshin M, Eist H (eds): *Psychiatry in the New Millennium.* Ebert. Sept 737
Work Group on Delirium of the American Psychiatric Association: *Practice Guidelines for the Treatment of Patients With Delirium.* Kwentus. Jan 64

Borderline Personality Disorder
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder [letter]. Hough. Apr 296–297
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Zanarini. Nov 849–854
Preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Hollander. Mar 199–203

Brainstorms
Does evidence from clinical trials in psychopharmacology apply in clinical practice? Stahl. Jan 6–7
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 1: "Goldilocks" actions at dopamine receptors. Stahl. Nov 841–842
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 2: illustrating their mechanism of action. Stahl. Dec 923–924
Effects of estrogen on the central nervous system. Stahl. May 317–318
Fibromyalgia: the enigma and the stigma. Stahl. July 501–502
Gut feelings about irritable bowel syndrome. Stahl. Aug 590–591
"Hit-and-run" actions at dopamine receptors, pt 1: mechanism of action of atypical antipsychotics. Stahl. Sept 670–671
"Hit-and-run" actions at dopamine receptors, pt 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. Stahl. Oct 747–748
Natural estrogen as an antidepressant for women. Stahl. June 404–405
Psychopharmacology of sex, pt 1: neurotransmitters and the 3 phases of the human sexual response. Stahl. Feb 80–81
Psychopharmacology of sex, pt 2: effects of drugs and disease on the 3 phases of human sexual response. Stahl. Mar 147–148
Why drugs and hormones may interact in psychiatric disorders. Stahl. Apr 225–226

Breastfeeding
Serum fluvoxamine levels in breastfed infants. Piontek. Feb 111–113

Brief Psychiatric Rating Scale
Use of the Brief Psychiatric Rating Scale to facilitate differential diagnosis at acute inpatient admission [CME]. Hopko. Apr 304–312

Bulimia Nervosa
Open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Lam RW. Mar 164–168

Bupropion
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. Chengappa. July 503–508
Bupropion sustained release for bereavement: results of an open trial. Zisook. Apr 227–230
Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Trivedi. Oct 776–781
Seizure during combination of trimipramine and bupropion [letter]. Enns. June 476–477
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. Clayton. Mar 185–190

Buspirone
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg. June 448–452
Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder [letter]. Arató. Aug 657–658

Cardiac Safety
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Czekalla. Suppl 2, 35–40

Cardiovascular System
Consensus statement on depression, anxiety, and cardiovascular disease. Ballenger. Suppl 8, 24–27
Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. Sheps. Suppl 8, 12–16
Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. Roose. Suppl 8, 19–22

Chilaiditi syndrome
Chilaiditi syndrome–associated schizophrenia: 3 case reports [letter]. Miyaoka. Jan 58–59

Children
Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. Wozniak. Suppl 14, 10–15
Neuroleptic-related dyskinesias in children and adolescents [CME]. Connor DF. Dec 967–974
Posttraumatic stress disorder in the general population and in children. Yule. Suppl 17, 23–28

Citalopram
Citalopram as adjunctive therapy in bipolar depression. Kupfer. Dec 985–990
Citalopram in the maintenance treatment of major depressive disorder [letter]. Sonawalla. Dec 993
Citalopram treatment of fluoxetine nonresponders. Thase. Sept 683–687

Clinical Trials
Clinical trial design issues in schizophrenic research. Casey. Suppl 9, 17–20
Concluding discussion: Evaluating clinical trial data from schizophrenia research. Suppl 9, 44–45
Dose selection and comparator drugs in schizophrenia research. Kane. Suppl 9, 29–32
Evaluating characteristics of patient selection and dropout rates. Keith. Suppl 9, 11–14
Evaluating clinical trial data: outcome measures. Conley. Suppl 9, 23–26
Hypothesis and hypothesis testing in the clinical trial. Lieberman. Suppl 9, 5–8
Interpretations and conclusions in the clinical trial. Docherty. Suppl 9, 40–43
Introduction: evaluating clinical trial data from schizophrenia research. Tamminga. Suppl 9, 3–4
Statistical comparison of clinical trials. Schooler. Suppl 9, 35–37

Clozapine
Addition of risperidone to clozapine therapy in chronically psychotic inpatients [letter]. de Groot. Feb 129–130
Branded versus generic clozapine: bioavailability comparison and interchangeability issues. Lam YWF. Suppl 5, 18–22
Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. Kluznik. Suppl 5, 14–17
Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. Henderson DC. Suppl 23, 39–44
Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. Chen NC. June 479–480
Clozapine in the treatment of hypomania with neurosyphilis [letter]. Mahendran. June 477–478
Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Aizenberg. July 541–544

Conclusion: comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky, Suppl 5, 27–27
Increase in plasma levels of clozapine and norclozapine after administration of nefazodone [letter]. Khan AY, May 375–376
Introduction: comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky, Suppl 5, 3
Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. Hägg, Nov 843–848
Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. Lane, Oct 812–817
Risperidone added to clozapine: impact on serum prolactin levels. Henderson DC, Aug 605–608

Cocaine
Gabapentin in the treatment of cocaine dependence: a case series. Myrick, Jan 19–23

Cognition
Cognitive side effects of anticonvulsants. Goldberg, Suppl 14, 27–33

Comorbidity
Comorbidity of Axis I disorders in patients with traumatic grief. Melhem, Nov 884–887
Social anxiety disorder: comorbidity and its implications. Lydiard, Suppl 1, 17–23

Compulsive Skin Picking
Inositol in the treatment of trichotillomania and compulsive skin picking [letter]. Seedat, Jan 60–61

Consensus Statements
Consensus statement on depression, anxiety, and cardiovascular disease. Ballenger, Suppl 8, 24–27
Consensus statement on depression, anxiety, and functional gastrointestinal disorders. Ballenger, Suppl 8, 48–51
Consensus statement on depression, anxiety, and oncology. Ballenger, Suppl 8, 64–67
Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 11, 53–58
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 13, 47–55

Continuing Medical Education (CME)
Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Valenstein, July 545–551
Advances and Emerging Treatments in Social Phobia, Suppl 1, 1–56
Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. Jin, Oct 797–803
Chronic Major Depression: A Review and Update. Suppl 6, 1–37
Clinical features of bipolar depression: a comparison with matched major depressive disorder patients. Mitchell PB, Mar 212–216
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. Miller DS, Dec 975–980
Determinants of overweight and obesity in patients with bipolar disorder. Elmslie, June 486–491
Effects of Atypical Antipsychotics on Body Weight and Glucose Regulation. Suppl 23, 1–69
Evaluating Clinical Trial Data From Schizophrenia Research. Suppl 9, 1–48
Familial psychiatric illness and posttraumatic stress disorder: findings from a family study of substance abuse and anxiety disorders. Dierker, Sept 715–720
Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? Bloch, Nov 855–859
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Alonso, July 535–540
Management of Treatment-Resistant Depression, Suppl 18, 1–36
Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. Grunebaum, May 394–399
Metabolic Disturbances Associated With Antipsychotic Use. Suppl 27, 1–44
Neuroleptic-related dyskinesias in children and adolescents. Connor DF, Dec 967–974
New Developments for Treating Sleep Disorders, Suppl 10, 1–48
One-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. Ballard, Aug 631–636
Optimizing Depression Treatments Throughout the Life Cycle, Suppl 24, 1–25
Pathways to Suicide Prevention for Bipolar Disorder, Suppl 25, 1–68
Recognizing Treatment-Resistant Depression, Suppl 16, 1–38
Record-based analysis of 803 patients treated for depression in psychiatric care. Rytsälä, Sept 701–706
Remission of Anxiety-Related Disorders. Suppl 12, 1–38
Role of Anticonvulsants as Mood Stabilizers, Suppl 14, 1–44
Sexual Dysfunction Associated With Depression and Its Treatment. Suppl 3, 1–46
Suicide in primary affective disorders revisited: a systematic review by treatment era. O'Leary, Oct 804–811
Trauma and stress: diagnosis and treatment [Academic Highlights]. Nov 906–915
Use of the Brief Psychiatric Rating Scale to facilitate differential diagnosis at acute inpatient admission. Hopko, Apr 304–312
Why do young women diet? the roles of body fat, body perception, and body ideal. Gruber, Aug 609–611

Corrections
Detection of insomnia in primary care. Doghramji, Suppl 10, 18–26; Correction, Aug 658
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Lesem, Jan 12–18; Correction, Mar 209
Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study [CME]. Grunebaum, May 394–399; Correction, June 480
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Pollack, May 350–357; Correction, Aug 658
Review of Allen JG: *Coping With Trauma: A Guide to Self-Understanding*. Nizny, 2000;61:953–954; Correction, Mar 209

Corticosteroids
Lithium therapy for corticosteroid-induced mood disorder [letter]. Terao; Wada reply, Jan 57–58

Costs of Medical Care
Cost savings with intramuscular anticholinergics [letter]. Markowitz, Apr 295
Service use and costs of treating schizophrenia with atypical antipsychotics. Lewis M, Oct 749–756
Societal costs of chronic major depression. Pincus, Suppl 6, 5–9

Creutzfeldt-Jakob Disease
Psychotic symptoms presented in familial Creutzfeldt-Jakob disease, subtype E200K [letter]. Zeng, Sept 734–735

Cutaneous Reactions
Cutaneous reactions to anticonvulsant medications. Hebert, Suppl 14, 22–26

Dementia
Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. Finkel, Suppl 21, 3–6
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. Rainer, Nov 894–900
Emergence of PTSD in trauma survivors with dementia [letter]. van Achterberg, Mar 206–207
Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. Ballard, Jan 46–49
One-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments [CME]. Ballard, Aug 631–636
Risperidone for the treatment of behavioral and psychological symptoms of dementia. Tune, Suppl 21, 29–32
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. De Deyn, Suppl 21, 19–22

Depersonalization Disorder
Lamotrigine in the treatment of depersonalization disorder [letter]. Sierra, Oct 826–827

Depression
Acute and maintenance treatment of chronic depression. Dunner, Suppl 6, 10–16
Algorithm for the treatment of chronic depression. Trivedi, Suppl 6, 22–29
Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients [CME]. Jin, Oct 797–803
Augmentation and combination strategies in treatment-resistant depression. Fava M, Suppl 18, 4–11
Biological differences in depression and anxiety across races and ethnic groups. Lin, Suppl 13, 13–19
Bipolar rapid cycling: focus on depression as its hallmark. Calabrese, Suppl 14, 34–41
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective

serotonin reuptake inhibitor antidepressants. Chengappa, July 503–508
Burden of depression and anxiety in general medicine. Lecrubier, Suppl 8, 4–9
Burden of disease for treatment-resistant depression. Greden, Suppl 16, 26–31
Burden of recurrent depression: causes, consequences, and future prospects. Greden, Suppl 22, 5–9
Changing paradigms: depressed patients as treatment partners [letter]. Hagerty, June 478–479
Characterizing the ideal antidepressant therapy to achieve remission. Ferrier, Suppl 26, 10–15
Chronic Major Depression: A Review and Update. Suppl 6, 1–37
Citalopram in the maintenance treatment of major depressive disorder [letter]. Sonawalla, Dec 993
Clinical features of bipolar depression: a comparison with matched major depressive disorder patients [CME]. Mitchell PB, Mar 212–216
Clinical features of treatment-resistant depression. Kornstein, Suppl 16, 18–25
Clinician perspective on achieving and maintaining remission in depression. Kelsey, Suppl 26, 16–21
Consensus statement on depression, anxiety, and cardiovascular disease. Ballenger, Suppl 8, 24–27
Consensus statement on depression, anxiety, and functional gastrointestinal disorders. Ballenger, Suppl 8, 48–51
Consensus statement on depression, anxiety, and oncology. Ballenger, Suppl 8, 64–67
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 13, 47–55
Consumer perspective of diagnosis and treatment of chronic major depression. Lewis LJ, Suppl 6, 30–34
Contemporary management of comorbid anxiety and depression in geriatric patients. Doraiswamy, Suppl 12, 30–35
Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. Kirmayer, Suppl 13, 22–28
Definition and meaning of treatment-resistant depression. Sackeim, Suppl 16, 10–17
Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. Nierenberg, Suppl 16, 5–9
Depression and anxiety in oncology: the oncologist's perspective. Jones RD, Suppl 8, 52–55
Depression and anxiety in oncology: the psychiatrist's perspective. Berard, Suppl 8, 58–61
Depression and quality of life: a patient's perspective. Singleton, Suppl 26, 22
Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. Sheps, Suppl 8, 12–16
Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. Roose, Suppl 8, 19–22
Depression, anxiety, and the gastrointestinal system. Mayer, Suppl 8, 28–36
Diagnosing and treating depression in the elderly. Nelson JC, Suppl 24, 18–22
Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Trivedi, Oct 776–781
Double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Mulsant, Aug 597–604
Economic and social burden of depression. Sartorius, Suppl 15, 8–11
Effects of antidepressants on sexual functioning in depressed patients: a review. Ferguson, Suppl 3, 22–34
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. Fava M, June 413–420
Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. Dinan, Suppl 22, 48–52
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Thase, Oct 782–788
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH, July 523–529
Epidemiology, burden, and disability in depression and anxiety. Lépine, Suppl 13, 4–10
Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. Ahokas, May 332–336
Evaluation and management of depression in women across the life span. Kornstein, Suppl 24, 11–17
Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. Burke, Suppl 22, 38–42
Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. Reimherr, Suppl 22, 16–23
Fluoxetine: a suitable long-term treatment. Calil, Suppl 22, 24–29
Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. Pyne, Apr 261–268
Integrated treatment of comorbid depression and substance use disorders. Charney, Sept 672–677
Introduction. Chronic major depression: a review and update. Rush, Suppl 6, 3–4
Introduction. Depression: the relevance of the time factor. Pinder, Suppl 15, 5–7
Introduction: focus on depression and anxiety disorders in general medicine. Suppl 8, 3
Introduction: focus on transcultural issues in depression and anxiety. Ballenger, Suppl 13, 3
Introduction: management of treatment-resistant depression. Rush, Suppl 18, 3
Introduction. Optimizing outcomes of treating depression: meeting patient expectations. Wittchen, Suppl 26, 3–4
Introduction: recognizing treatment-resistant depression. Rush, Suppl 16, 3–4
Introduction: role of enteric-coated fluoxetine once-weekly in achieving optimal outcomes in the long-term treatment of depression. Kupfer, Suppl 22, 3–4
Introduction: sexual dysfunction associated with depression. Rothschild, Suppl 3, 3–4
Irritable bowel syndrome, anxiety, and depression: what are the links? Lydiard, Suppl 8, 38–45
Long-term management of chronic depression. Nierenberg, Suppl 6, 17–21
Long-term treatment of recurrent and chronic depression. Keller, Suppl 24, 3–5
Management of treatment-resistant depression: psychotherapeutic perspectives. Thase, Suppl 18, 18–24
Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Tajima, Suppl 13, 39–44
Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. Wittchen, Suppl 26, 23–28
Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. Ballard, Jan 46–49
Need for clinically relevant research on treatment-resistant depression [commentary]. Thase, Apr 221–224
New standard of depression treatment: remission and full recovery. Bakish, Suppl 26, 5–9
Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. de Klerk, Suppl 22, 43–47
Patient perspectives on once-weekly fluoxetine. Judge, Suppl 22, 53–57
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg, June 448–452
Prescribing patterns for depression and anxiety worldwide. Lecrubier, Suppl 13, 31–36
Prevalence, recognition, and treatment of comorbid depression and anxiety. Rapaport, Suppl 24, 6–10
Prevention of recurrent postpartum depression: a randomized clinical trial. Wisner, Feb 82–86
Recognition and assessment of sexual dysfunction associated with depression. Clayton, Suppl 3, 5–9
Record-based analysis of 803 patients treated for depression in psychiatric care [CME]. Rytsälä, Sept 701–706
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Ferguson, Jan 24–29
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Entsuah, Nov 869–877
Societal costs of chronic major depression. Pincus, Suppl 6, 5–9
Switching antidepressants for treatment-resistant major depression. Marangell, Suppl 18, 13–17
Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients [CME]. Posternak, Feb 135–142
Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. Seidman, June 406–412
Treatment of refractory major depression with tramadol monotherapy [letter]. Shapira, Mar 205–206

Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. Frank, Suppl 22, 10–15
Understanding depression: a long-term, recurring disorder [Academic Highlights]. May 379–392
Using treatment algorithms for the effective management of treatment-resistant depression. Trivedi, Suppl 18, 25–29
Venlafaxine in the treatment of postpartum depression. Cohen LS, Aug 592–596
Which depressed patients respond to nefazodone and when? Trivedi, 158–163

Diabetes Mellitus
Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. Henderson DC, Suppl 23, 39–44
Diagnosis, classification, and pathogenesis of diabetes mellitus. Lebovitz, Suppl 27, 5–9
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose [letter]. Van Meter, Dec 993–994
Treatment of preexisting diabetes with olanzapine [letter]. Littrell, Sept 733–734

Diagnosis, Differential
Use of the Brief Psychiatric Rating Scale to facilitate differential diagnosis at acute inpatient admission [CME]. Hopko, Apr 304–312

Divalproex Sodium
Open trial of divalproex sodium in autism spectrum disorders. Hollander, July 530–534
Preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Hollander, Mar 199–203

Donepezil
Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. Miyaoka, July 573–574
Treatment of tardive dyskinesia with donepezil: a pilot study. Caroff, Oct 772–775
Treatment of tardive dyskinesia with donepezil [letter]. Caroff, Feb 128–129

Doxepin
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. Hajak, June 453–463

Drug Administration Routes
Efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Jones B, Suppl 2, 22–24
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Currier, Mar 153–157

Drug Therapy, Combination
Augmentation and combination strategies in treatment-resistant depression. Fava M, Suppl 18, 4–11

Dyskinesia
Neuroleptic-related dyskinesias in children and adolescents [CME]. Connor DF, Dec 967–974

Eating Disorders see also Bulimia Nervosa
Topiramate abuse in a bipolar patient with an eating disorder [letter]. Colom, June 475–476

Elderly
Anticholinergic effects of medication in elderly patients. Tune, Suppl 21, 11–14
Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients [CME]. Jin, Oct 797–803
Contemporary management of comorbid anxiety and depression in geriatric patients. Doraiswamy, Suppl 12, 30–35
Diagnosing and treating depression in the elderly. Nelson JC, Suppl 24, 18–22
Double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Mulsant, Aug 597–604

Electroconvulsive Therapy
ECT and onset of action. Roose, Suppl 4, 24–26
Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. Krahn, Feb 108–110
Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. Ciapparelli, July 552–555

Fibromyalgia
Fibromyalgia: the enigma and the stigma [Brainstorms]. Stahl, July 501–502

Fluoxetine
Citalopram treatment of fluoxetine nonresponders. Thase, Sept 683–687
Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. Dinan, Suppl 22, 48–52
Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. Burke, Suppl 22, 38–42
Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. Reimherr, Suppl 22, 16–23
Fluoxetine: a suitable long-term treatment. Calil, Suppl 22, 24–29
Introduction: role of enteric-coated fluoxetine once-weekly in achieving optimal outcomes in the long-term treatment of depression. Kupfer, Suppl 22, 3–4
Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. de Klerk, Suppl 22, 43–47
Patient perspectives on once-weekly fluoxetine. Judge, Suppl 22, 53–57

Fluvoxamine
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. Phillips KA, Feb 87–91
Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. Silvestri, Aug 642–652
Serum fluvoxamine levels in breastfed infants. Piontek, Feb 111–113
Sexual dysfunction and fluvoxamine therapy [letter]. Waldinger; Nafziger reply, Feb 126–128

Food and Drug Administration
United States Food and Drug Administration requirements for approval of generic drug products. Meyer, Suppl 5, 4–9

Gabapentin
Gabapentin for the treatment of patients with somatization disorder [letter]. García-Campayo, June 474
Gabapentin in the treatment of cocaine dependence: a case series. Myrick, Jan 19–23

Gastrointestinal System
Consensus statement on depression, anxiety, and functional gastrointestinal disorders. Ballenger, Suppl 8, 48–51
Depression, anxiety, and the gastrointestinal system. Mayer, Suppl 8, 28–36
Irritable bowel syndrome, anxiety, and depression: what are the links? Lydiard, Suppl 8, 38–45

Gender
Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. Demyttenaere, Suppl 22, 34–37

Generalized Anxiety Disorder see also Anxiety
Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. Sheehan, Suppl 19, 26–31
Comorbidity in generalized anxiety disorder: impact and implications. Stein DJ, Suppl 11, 29–34
Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 11, 53–58
Dissolving the burden of generalized anxiety disorder. Ninan, Suppl 19, 5–10
Generalized anxiety disorder: nature and course. Wittchen, Suppl 11, 15–19
Introduction: focus on generalized anxiety disorder. Ballenger, Suppl 11, 3
Introduction. Generalized anxiety disorder: why are we failing our patients? Ninan, Suppl 19, 3–4
Neurobiological mechanisms in generalized anxiety disorder. Nutt, Suppl 11, 22–27
Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. Pollack, Suppl 19, 20–25
Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. Ballenger, Suppl 19, 11–19
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Meoni, Nov 888–893
Pharmacotherapy of generalized anxiety disorder. Davidson JRT, Suppl 11, 46–50
Psychotherapy for generalized anxiety disorder. Borkovec, Suppl 11, 37–42
Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder [letter]. Arató, Aug 657–658
What is generalized anxiety disorder? Rickels, Suppl 11, 4–12

Genetics
Genetic dissection of atypical antipsychotic–induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile, Suppl 23, 45–66

Geriatric Psychiatry see Elderly

Ginkgo biloba
Double-blind, placebo-controlled trial of extract of *Ginkgo biloba* added to haloperidol in treatment-resistant patients with schizophrenia. Zhang, Nov 878–883

Glucose
Apparent effects of ziprasidone on plasma lipids and glucose. Kingsbury, May 347–349
Introduction: weight gain and glucose regulation during antipsychotic drug treatment. Sussman, Suppl 23, 3–4

Granisetron
Placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction. Nelson EB, June 469–473

Grapefruit Juice
Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. Lane, Oct 812–817
Grief
Comorbidity of Axis I disorders in patients with traumatic grief. Melhem, Nov 884–887
Hair pulling see Trichotillomania
Haloperidol
Double-blind, placebo-controlled trial of extract of *Ginkgo biloba* added to haloperidol in treatment-resistant patients with schizophrenia. Zhang, Nov 878–883
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Basson, Apr 231–238
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. Rabinowitz, May 343–346
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Currier, Mar 153–157
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez, Suppl 2, 6–11
Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. Silver, Sept 707–714
Harvard/Brown Anxiety Disorders Research Program
Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown Anxiety Disorders Research Program. Salzman, Mar 149–152
HIV
Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia. Walkup, Mar 174–178
Hormones
Effects of estrogen on the central nervous system [Brainstorms]. Stahl, May 317–318
Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. Ahokas, May 332–336
Natural estrogen as an antidepressant for women [Brainstorms]. Stahl, June 404–405
Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. Seidman, June 406–412
Why drugs and hormones may interact in psychiatric disorders [Brainstorms]. Stahl, Apr 225–226
Hyperglycemia
Hyperglycemia and antipsychotic medications. Haupt, Suppl 27, 15–26
Hyperglycemia associated with the use of atypical antipsychotics. Lindenmayer, Suppl 23, 30–38
Hypomania
Clozapine in the treatment of hypomania with neurosyphilis [letter]. Mahendran, June 477–478
Reboxetine-induced hypomania [letter]. Vieta, Aug 655–656
Hypothermia
Hypothermia in 2 patients treated with atypical antipsychotic medication [letter]. Parris, Jan 61–63
Inositol
Inositol in the treatment of trichotillomania and compulsive skin picking [letter]. Seedat, Jan 60–61
Insomnia
Consequences of insomnia and its therapies. Benca, Suppl 10, 33–38
Detection of insomnia in primary care. Doghramji, Suppl 10, 18–26; Correction, Aug 658
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. Hajak, June 453–463
Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. Krahn, Feb 108–110
Future directions in the management of insomnia. Richardson, Suppl 10, 39–45
Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. Andrade, Jan 41–45
Psychiatric perspective on insomnia. McCall, Suppl 10, 27
Sleep architecture and its relationship to insomnia. Erman, Suppl 10, 9–17
Insurance Claim Review
Family member's legal experience with an insurer's refusal to recertify inpatient mental health treatment. Shyovitz, Suppl 25, 44–50
Internet
Internet-observed suicide attempts [letter]. Janson, June 478
Irritable Bowel Syndrome
Gut feelings about irritable bowel syndrome [Brainstorms]. Stahl, Aug 590–591
Irritable bowel syndrome, anxiety, and depression: what are the links? Lydiard, Suppl 8, 38–45
Japan
Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Tajima, Suppl 13, 39–44
Journal of Clinical Psychiatry
From print to E-ternity. July 499–500
Many thanks. Gelenberg, Jan 3–5
Lamotrigine
Lamotrigine in the treatment of depersonalization disorder [letter]. Sierra, Oct 826–827
Leptin
Body weight gain, insulin, and leptin in olanzapine-treated patients [letter]. Baptista; Melkersson reply, Nov 902–904
Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. Hägg, Nov 843–848
Light Therapy see Phototherapy
Limbic Leucotomy
Improvement in severe self-mutilation following limbic leucotomy: a series of 5 consecutive cases. Price, Dec 925–932
Lipids
Apparent effects of ziprasidone on plasma lipids and glucose. Kingsbury, May 347–349
Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. Henderson DC, Suppl 23, 39–44
Lithium
Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. Fava GA, July 556–559
Lithium intoxication after administration of AT_1 blockers [letter]. Zwanzger, Mar 208–209
Lithium therapy for corticosteroid-induced mood disorder [letter]. Terao; Wada reply, Jan 57–58
Thiazide diuretics and lithium levels [letter]. Berkowitz, Jan 57
Lorazepam
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Currier, Mar 153–157
Managed Care
One-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments [CME]. Ballard, Aug 631–636
Mania
Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Preda, Jan 30–33
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania [CME]. Miller DS, Dec 975–980
Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. Ciapparelli, July 552–555
Mannitol-induced acute manic state [letter]. Navarro, Feb 126
Mannitol
Mannitol-induced acute manic state [letter]. Navarro, Feb 126
Medicaid
Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia. Walkup, Mar 174–178
Medical Illness
Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. Andrade, Jan 41–45
Melatonin
Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. Andrade, Jan 41–45
Men
Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. Seidman, June 406–412
Mental Retardation
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Cohen S, Feb 114–116
Metabolism
Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. Henderson DC, Suppl 27, 10–14
Introduction: metabolic disturbances associated with antipsychotic use. Newcomer, Suppl 27, 3–4
Metabolic Disturbances Associated With Antipsychotic Use. Suppl 27, 1–44
Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. Meltzer, Suppl 27, 35–39
Metformin
Metformin in obesity associated with antipsychotic drug administration: a pilot study [letter]. Baptista, Aug 653–655

Minerals
Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? [commentary] Popper, Dec 933–935
Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. Kaplan, Dec 936–944
Mirtazapine
Does mirtazapine have a more rapid onset than SSRIs? Quitkin, May 358–361
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. Fava M, June 413–420
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Thase, Oct 782–788
Mirtazapine-associated palinopsia [letter]. Ihde-Scholl, May 373
Miscarriage
Anxiety disorders following miscarriage. Geller, June 432–438
Mood
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania [CME]. Miller DS, Dec 975–980
Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? [commentary] Popper, Dec 933–935
Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. Kaplan, Dec 936–944
Indicators of suicide over 10 years in a specialist mood disorders unit sample. Gladstone, Dec 945–951
Introduction: role of anticonvulsants as mood stabilizers. Bowden, Suppl 14, 3–4
Lithium therapy for corticosteroid-induced mood disorder [letter]. Terao; Wada reply, Jan 57–58
Mood disorder history and personality assessment in premenstrual dysphoric disorder. Critchlow, Sept 688–693
Mood disorders and suicide. Nierenberg, Suppl 25, 27–30
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. Narendran, July 509–516
Quetiapine alone and added to a mood stabilizer for serious mood disorders. Sajatovic, Sept 728–732
Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder. Patten, May 319–324
Movement Disorders see also specific disorders
Movement disorders associated with neuroleptic treatment. Wirshing WC, Suppl 21, 15–18
Nefazodone
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor– and imipramine-controlled trials. Sussman, Apr 256–260
Increase in plasma levels of clozapine and norclozapine after administration of nefazodone [letter]. Khan AY, May 375–376
Open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. Gillin, Oct 789–796
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Ferguson, Jan 24–29
Remission of SSRI-induced akathisia after switch to nefazodone [letter]. Chelben, July 570–571
Which depressed patients respond to nefazodone and when? Trivedi, Mar 158–163
Neuroimaging
Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. Pitman, Suppl 17, 47–54
Neurosyphilis
Clozapine in the treatment of hypomania with neurosyphilis [letter]. Mahendran, June 477–478
Neurotransmitters
Neurotransmitters and sleep. Mendelson, Suppl 10, 5–8
Nicotine
Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. Silver, Sept 707–714
Nortriptyline
Double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Mulsant, Aug 597–604
Nose Picking see Rhinotillexomania
Obesity
Schizophrenia, obesity, and obstructive sleep apnea. Winkelman, Jan 8–11
Obsessive-Compulsive Disorder
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy [CME]. Alonso, July 535–540
Patterns of temperament and character in subjects with obsessive-compulsive disorder. Lyoo, Aug 637–641
Retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder [CME]. Saxena, Jan 67–72
Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. Sachdev, Dec 981–984
Obstructive Sleep Apnea
Schizophrenia, obesity, and obstructive sleep apnea. Winkelman, Jan 8–11
Olanzapine
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Czekalla, Mar 191–198
Body weight gain, insulin, and leptin in olanzapine-treated patients [letter]. Baptista; Melkersson reply, Nov 902–904
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Czekalla, Suppl 2, 35–40
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon, Suppl 2, 17–21
Effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Clark, Jan 34–40
Effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Davis, Oct 757–771
Efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. Marténvi, Suppl 2, 25–27
Efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Jones B, Suppl 2, 22–24
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach, Suppl 2, 28–34
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Basson, Apr 231–238
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Sanger, Apr 273–281
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Kinon, Feb 92–100
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder [letter]. Hough, Apr 296–297
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases [letter]. Agarwal, Apr 298–299
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose [letter]. Van Meter, Dec 993–994
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. Narendran, July 509–516
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Zanarini, Nov 849–854
Olanzapine versus other antipsychotics in the treatment of schizophrenia [letter] Masand; Sacristán reply, Oct 828–829
Open-label study of the treatment efficacy of olanzapine for Tourette's disorder. Budman, Apr 290–294
Rapid tranquilization with olanzapine in acute psychosis: a case series. Karagianis, Suppl 2, 12–16
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report [letter]. Grant, Apr 297–298
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez, Suppl 2, 6–11
Treatment of preexisting diabetes with olanzapine [letter]. Littrell, Sept 733–734
Oncology
Consensus statement on depression, anxiety, and oncology. Ballenger, Suppl 8, 64–67
Depression and anxiety in oncology: the oncologist's perspective. Jones RD, Suppl 8, 52–55
Depression and anxiety in oncology: the psychiatrist's perspective. Berard, Suppl 8, 58–61
Palinopsia
Mirtazapine-associated palinopsia [letter]. Ihde-Scholl, May 373

Panic Disorder
Effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. Roy-Byrne, Sept 678–682
Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. Zwanzger, Aug 656–657
Paroxetine
Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. Silvestri, Aug 642–652
Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study [letter]. Jockers-Scherübl, July 573
Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Tucker, Nov 860–868
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Pollack, May 350–357; Correction, Aug 658
Pathological Gambling
Demographic and clinical features of 131 adult pathological gamblers. Grant, Dec 957–962
Patients
Patient perspectives on once-weekly fluoxetine. Judge, Suppl 22, 53–57
Perphenazine
Double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Mulsant, Aug 597–604
Pharmaceutical Industry
Commentary. Grow the market. Gelenberg, Aug 589
Pharmacokinetics
Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. Cutler, Suppl 5, 10–13
Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. Lane, Oct 812–817
Phototherapy
Open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Lam RW, Mar 164–168
Physical Restraint
Physical restraints, thromboembolism, and death in 2 patients [letter]. Lazarus, Mar 207–208
Pimozide
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Bruggeman, Jan 50–56
Pisa Syndrome
Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. Miyaoka, July 573–574
Positive Symptoms
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon, Suppl 2, 17–21
Efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Jones B, Suppl 2, 22–24
Posttraumatic Stress Disorder
Acute posttraumatic stress: nonacceptance of early intervention. Weisæth, Suppl 17, 35–40
Biology of posttraumatic stress disorder. Yehuda, Suppl 17, 41–46
Emergence of PTSD in trauma survivors with dementia [letter]. van Achterberg, Mar 206–207
Epidemiology of posttraumatic stress disorder: what is the extent of the problem? Breslau, Suppl 17, 16–22
Familial psychiatric illness and posttraumatic stress disorder: findings from a family study of substance abuse and anxiety disorders [CME]. Dierker, Sept 715–720
Impact of posttraumatic stress disorder in military situations. Solomon Z, Suppl 17, 11–15
Introduction. Understanding posttraumatic stress disorder (PTSD): an overview. Yehuda, Suppl 17, 3
Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. Pitman, Suppl 17, 47–54
Open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. Gillin, Oct 789–796
Outcomes of posttraumatic stress disorder. Breslau, Suppl 17, 55–59
Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Tucker, Nov 860–868
Posttraumatic stress disorder in the general population and in children. Yule, Suppl 17, 23–28
Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. Londborg, May 325–331
Topiramate in posttraumatic stress disorder: preliminary clinical observations. Berlant, Suppl 17, 60–63
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. Agid, Mar 169–173
Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. Rothbaum, Aug 617–622
What is posttraumatic stress disorder? Shalev, Suppl 17, 4–10
Women and traumatic events. Foa, Suppl 17, 29–34
Prediction Outcome
Clinical significance of monitoring early symptom change to predict outcome. Trivedi, Suppl 4, 27–33
Premenstrual Syndrome
Effects of the menstrual cycle on measures of personality in women with premenstrual syndrome: a preliminary study. Berlin, May 337–342
Mood disorder history and personality assessment in premenstrual dysphoric disorder. Critchlow, Sept 688–693
Priapism
Priapism associated with conventional and atypical antipsychotic medications: a review. Compton, May 362–366
Priapism associated with polypharmacy [letter]. Seger, Feb 128
Primary Care
Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. Demyttenaere, Suppl 22, 30–33
Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. Demyttenaere, Suppl 22, 34–37
Detection of insomnia in primary care. Doghramji, Suppl 10, 18–26; Correction, Aug 658
Early onset of antidepressant action: impact on primary care. Culpepper, Suppl 4, 4–6
Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. Wittchen, Suppl 26, 23–28
Social anxiety disorder: an unrecognized problem in primary care. Katzelnick, Suppl 1, 11–15
Prolactin
Risperidone added to clozapine: impact on serum prolactin levels. Henderson DC, Aug 605–608
Psychosis see also specific diagnoses
Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Preda, Jan 30–33
Effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Clark, Jan 34–40
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Lesem, Jan 12–18; Correction, Mar 209
Introduction: a new era in the pharmacotherapy of psychotic disorders. Breier, Suppl 2, 3–5
Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study [CME]. Grunebaum, May 394–399; Correction, June 480
Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. Ballard, Jan 46–49
Rapid tranquilization with olanzapine in acute psychosis: a case series. Karagianis, Suppl 2, 12–16
Psychotherapy
Current status of psychotherapeutic interventions for social phobia. Heimberg, Suppl 1, 36–42
Psychotherapy for generalized anxiety disorder. Borkovec, Suppl 11, 37–42
Pulmonary Fibrosis
Bipolar affective disorder and idiopathic pulmonary fibrosis [letter]. Bhandari, July 574–575
QTc Interval
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Czekalla, Mar 191–198
Quality of Life
Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. Pyne, Apr 261–268
Quetiapine
Antiaggressive effect of quetiapine in a patient with schizoaffective disorder [letter]. Citrome, Nov 901
Quetiapine alone and added to a mood stabilizer for serious mood disorders. Sajatovic, Sept 728–732
Reboxetine
Reboxetine-induced hypomania [letter]. Vieta, Aug 655–656

Remission
Sensitizing clinicians and patients to the social and functional aspects of remission. Trivedi, Suppl 19, 32–35
Research Design
Development of study exit criteria for evaluating antimanic compounds. Frank, June 421–425
Methodology to measure onset of action. Thase, Suppl 15, 18–21
Problems with ensuring a double blind [letter]. Kumar S; Zanardi reply, Apr 295–296
Residential Care
Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study [CME]. Grunebaum, May 394–399; Correction, June 480
Rhinotillexomania
Preliminary survey of rhinotillexomania in an adolescent sample. Andrade, June 426–431
Risperidone
Addition of risperidone to clozapine therapy in chronically psychotic inpatients [letter]. de Groot, Feb 129–130
Comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Malla, Mar 179–184
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. Rainer, Nov 894–900
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Vieta, Aug 623–630
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach, Suppl 2, 28–34
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Basson, Apr 231–238
Long-term safety of risperidone. Davidson M, Suppl 21, 26–28
Optimal dosing with risperidone: updated recommendations. Williams R, Apr 282–289
Pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia [letter]. Lane, Dec 994–995
Randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Buitelaar, Apr 239–248
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. Rabinowitz, May 343–346
Risperidone added to clozapine: impact on serum prolactin levels. Henderson DC, Aug 605–608
Risperidone for the treatment of behavioral and psychological symptoms of dementia. Tune, Suppl 21, 29–32
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Currier, Mar 153–157
Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Vieta, Oct 818–825
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Bruggeman, Jan 50–56
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Cohen S, Feb 114–116
Schizoaffective Disorder
Antiaggressive effect of quetiapine in a patient with schizoaffective disorder [letter]. Citrome, Nov 901
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Vieta, Aug 623–630
Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder [letter]. Grieger, Jan 59–60
Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Vieta, Oct 818–825
Schizophrenia
Adherence assessments and the use of depot antipsychotics in patients with schizophrenia [CME]. Valenstein, July 545–551
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Czekalla, Mar 191–198
Antipsychotic-associated weight gain and clinical outcome parameters. Blin, Suppl 7, 11–21
Antipsychotic-induced weight gain: a review of the literature. Allison, Suppl 7, 22–31
Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients [CME]. Jin, Oct 797–803
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Czekalla, Suppl 2, 35–40
Chilaiditi syndrome–associated schizophrenia: 3 case reports [letter]. Miyaoka, Jan 58–59
Clinical implications of weight gain in schizophrenia. Kurzthaler, Suppl 7, 32–37
Clinical trial design issues in schizophrenic research. Casey, Suppl 9, 17–20
Comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Malla, Mar 179–184
Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Aizenberg, July 541–544
Concluding discussion: Evaluating clinical trial data from schizophrenia research. Suppl 9, 44–45
Dose selection and comparator drugs in schizophrenia research. Kane, Suppl 9, 29–32
Double-blind, placebo-controlled trial of extract of *Ginkgo biloba* added to haloperidol in treatment-resistant patients with schizophrenia. Zhang, Nov 878–883
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon, Suppl 2, 17–21
Effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Davis, Oct 757–771
Efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. Martényi, Suppl 2, 25–27
Efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Jones B, Suppl 2, 22–24
Evaluating characteristics of patient selection and dropout rates. Keith, Suppl 9, 11–14
Evaluating clinical trial data: outcome measures. Conley, Suppl 9, 23–26
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach, Suppl 2, 28–34
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Basson, Apr 231–238
Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia. Walkup, Mar 174–178
Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? [CME] Bloch, Nov 855–859
Introduction: evaluating clinical trial data from schizophrenia research. Tamminga, Suppl 9, 3–4
Introduction. Weight gain: a growing problem in schizophrenia management. Meltzer, Suppl 7, 3
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Kinon, Feb 92–100
Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study [letter]. Jockers-Scherübl, July 573
Olanzapine versus other antipsychotics in the treatment of schizophrenia [letter] Masand; Sacristán reply, Oct 828–829
Pharmacology of weight gain with antipsychotics. Casey, Suppl 7, 4–10
Pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia [letter]. Lane, Dec 994–995
Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. Lane, Oct 812–817
Schizophrenia, obesity, and obstructive sleep apnea. Winkelman, Jan 8–11
Service use and costs of treating schizophrenia with atypical antipsychotics. Lewis M, Oct 749–756
Smoking habits in bipolar and schizophrenic outpatients in southern Israel. Itkin, Apr 269–272
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez, Suppl 2, 6–11
Weight change and atypical antipsychotic treatment in patients with schizophrenia. Jones B, Suppl 2, 41–44
Seasonal Affective Disorder
Open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Lam RW, Mar 164–168
Selective Serotonin Reuptake Inhibitors
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. Chengappa, July 503–508
Does mirtazapine have a more rapid onset than SSRIs? Quitkin, May 358–361

Effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. Roy-Byrne, Sept 678–682
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy [CME]. Alonso, July 535–540
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg, June 448–452
Role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Naranjo, Suppl 20, 18–25
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. Clayton, Mar 185–190
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. Agid, Mar 169
Use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. Pettinati, Suppl 20, 26–31

Self-Mutilation

Improvement in severe self-mutilation following limbic leucotomy: a series of 5 consecutive cases. Price, Dec 925–932
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder [letter]. Hough, Apr 296–297

Sertraline

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Trivedi, Oct 776–781
Mean dose after splitting sertraline tablets [letter]. Matuschka, Oct 826
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Ferguson, Jan 24–29
Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. Londborg, May 325–331

Sexual Function

Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. Aizenberg, July 541–544
Effects of antidepressants on sexual functioning in depressed patients: a review. Ferguson, Suppl 3, 22–34
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Montejo, Suppl 3, 10–21
Introduction: sexual dysfunction associated with depression. Rothschild, Suppl 3, 3–4
Placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction. Nelson EB, June 469–473
Psychopharmacology of sex, pt 1: neurotransmitters and the 3 phases of the human sexual response [BRAINSTORMS]. Stahl, Feb 80–81
Psychopharmacology of sex, pt 2: effects of drugs and disease on the 3 phases of human sexual response. [BRAINSTORMS]. Stahl, Mar 147–148
Recognition and assessment of sexual dysfunction associated with depression. Clayton, Suppl 3, 5–9
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Ferguson, Jan 24–29
Sexual dysfunction and fluvoxamine therapy [letter]. Waldinger; Nafziger reply, Feb 126–128
Strategies for the treatment of antidepressant-related sexual dysfunction. Zajecka, Suppl 3, 35–43
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. Clayton, Mar 185–190

Sleep

Chronic assaultive behavior improved with sleep apnea treatment [letter]. Dennis, July 571–572
Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. Silvestri, Aug 642–652
Effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. Kooij, Dec 952–956
Introduction: new developments for treating sleep disorders. Roth, Suppl 10, 3–4
Neurotransmitters and sleep. Mendelson, Suppl 10, 5–8
Sleep architecture and its relationship to insomnia. Erman, Suppl 10, 9–17

Smoking

Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. Chengappa, July 503–508
Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder. Patten, May 319–324
Smoking habits in bipolar and schizophrenic outpatients in southern Israel. Itkin, Apr 269–272

Social Anxiety Disorder see Social Phobia

Social Phobia

Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). Jefferson, Suppl 1, 50–53
Characteristics of social phobia among persons with essential tremor. Schneier, May 367–372
Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. Pollack, Suppl 12, 24–29
Current status of psychotherapeutic interventions for social phobia. Heimberg, Suppl 1, 36–42
Introduction: advances and emerging treatments in social phobia. Davidson JRT, Suppl 1, 4
Social anxiety disorder: an unrecognized problem in primary care. Katzelnick, Suppl 1, 11–15
Social anxiety disorder: comorbidity and its implications. Lydiard, Suppl 1, 17–23
Social phobia: etiology, neurobiology, and treatment. Coupland, Suppl 1, 25–35
Social phobia: prevalence and diagnostic threshold. Lang, Suppl 1, 5–10
Treatment of social phobia with antidepressants. Schneier, Suppl 1, 43–48

Somatization Disorder

Gabapentin for the treatment of patients with somatization disorder [letter]. García-Campayo, June 474

Statistics

Statistical comparison of clinical trials. Schooler, Suppl 9, 35–37
Type II error and antidepressants [letter]. Walker JB; Weihs reply, May 373–375

Substance Use Disorders

Acronyms for substance use disorders [letter]. Bogenschutz, June 474–475
Familial psychiatric illness and posttraumatic stress disorder: findings from a family study of substance abuse and anxiety disorders [CME]. Dierker, Sept 715–720
Integrated treatment of comorbid depression and substance use disorders. Charney, Sept 672–677
Suicidality and substance abuse in affective disorders. Goldberg, Suppl 25, 35–43

Suicide

Identifying and managing suicide risk in bipolar patients. Oquendo, Suppl 25, 31–34
Indicators of suicide over 10 years in a specialist mood disorders unit sample. Gladstone, Dec 945–951
Integration of suicide prevention into outpatient management of bipolar disorder. Sachs, Suppl 25, 3–11
Internet-observed suicide attempts [letter]. Janson, June 478
Intervention research with persons at high risk for suicidality: safety and ethical considerations. Pearson, Suppl 25, 17–26
Mood disorders and suicide. Nierenberg, Suppl 25, 27–30
Pharmacologic interventions in suicide prevention. Tondo, Suppl 25, 51–55
Prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. Baca-García, July 560–564
Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. Gray, Suppl 25, 56–64
Suicidality and substance abuse in affective disorders. Goldberg, Suppl 25, 35–43
Suicide attempts in bipolar patients. López, Dec 963–966
Suicide in primary affective disorders revisited: a systematic review by treatment era [CME]. O'Leary, Oct 804–811
Suicide prevention: increasing education and awareness. Grandin, Suppl 25, 12–16

Switching

Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients [CME]. Posternak, Feb 135–142

Tardive Dyskinesia

Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases [letter]. Agarwal, Apr 298–299
Treatment of tardive dyskinesia with donepezil: a pilot study. Caroff, Oct 772–775
Treatment of tardive dyskinesia with donepezil [letter]. Caroff, Feb 128–129

Texas Medication Algorithm Project

Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. Suppes, June 439–447

Thiazide Diuretics

Thiazide diuretics and lithium levels [letter]. Berkowitz, Jan 57

Tiagabine

Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. Zwanzger, Aug 656–657

Topiramate
Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. Grunze, June 464–468
Auditory hallucinations associated with topiramate [letter]. Matthews, Aug 653
Topiramate abuse in a bipolar patient with an eating disorder [letter]. Colom, June 475–476
Topiramate in posttraumatic stress disorder: preliminary clinical observations. Berlant, Suppl 17, 60–63
Tourette's Disorder
Open-label study of the treatment efficacy of olanzapine for Tourette's disorder. Budman, Apr 290–294
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Bruggeman, Jan 50–56
Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. Silver, Sept 707–714
Tramadol
Treatment of refractory major depression with tramadol monotherapy [letter]. Shapira, Mar 205–206
Tranquilization
Rapid tranquilization with olanzapine in acute psychosis: a case series. Karagianis, Suppl 2, 12–16
Transcranial Magnetic Stimulation
Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. Sachdev, Dec 981–984
Transcultural Psychiatry
Biological differences in depression and anxiety across races and ethnic groups. Lin, Suppl 13, 13–19
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 13, 47–55
Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. Kirmayer, Suppl 13, 22–28
Economic and social burden of depression. Sartorius, Suppl 15, 8–11
Epidemiology, burden, and disability in depression and anxiety. Lépine, Suppl 13, 4–10
Introduction: focus on transcultural issues in depression and anxiety. Ballenger, Suppl 13, 3
Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Tajima, Suppl 13, 39–44
Prescribing patterns for depression and anxiety worldwide. Lecrubier, Suppl 13, 31–36
Trauma
Comorbidity of Axis I disorders in patients with traumatic grief. Melhem, Nov 884–887
Trauma and stress: diagnosis and treatment [CME, ACADEMIC HIGHLIGHTS]. Nov 906–915
Trazodone
Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. Krahn, Feb 108–110
Tremor
Characteristics of social phobia among persons with essential tremor. Schneier, May 367–372
Trichotillomania
Inositol in the treatment of trichotillomania and compulsive skin picking [letter]. Seedat, Jan 60–61
Longitudinal follow-up of naturalistic treatment outcome in patients with trichotillomania. Keuthen, Feb 101–107
Triiodothyronine
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. Agid, Mar 169
Trimipramine
Seizure during combination of trimipramine and bupropion [letter]. Enns, June 476–477
Venlafaxine
Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. Sheehan, Suppl 19, 26–31
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH, July 523–529
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Meoni, Nov 888–893
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Entsuah, Nov 869–877
Venlafaxine in the treatment of postpartum depression. Cohen LS, Aug 592–596
Virtual Reality Exposure
Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. Rothbaum, Aug 617–622
Vitamins
Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? [commentary] Popper, Dec 933–935
Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. Kaplan, Dec 936–944
Weight
Antipsychotic-associated weight gain and clinical outcome parameters. Blin, Suppl 7, 11–21
Antipsychotic-induced weight gain: a review of the literature. Allison, Suppl 7, 22–31
Body weight gain, insulin, and leptin in olanzapine-treated patients [letter]. Baptista; Melkersson reply, Nov 902–904
Clinical implications of weight gain in schizophrenia. Kurzthaler, Suppl 7, 32–37
Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. Henderson DC, Suppl 23, 39–44
Determinants of overweight and obesity in patients with bipolar disorder [CME]. Elmslie, June 486–491
Effects of atypical antipsychotics on weight and serum lipid levels. Meyer JM, Suppl 27, 27–34
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor– and imipramine-controlled trials. Sussman, Apr 256–260
Epidemiology, morbidity, and treatment of overweight and obesity. Aronne, Suppl 23, 13–22
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Basson, Apr 231–238
Genetic dissection of atypical antipsychotic–induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile, Suppl 23, 45–66
Introduction. Weight gain: a growing problem in schizophrenia management. Meltzer, Suppl 7, 3
Introduction: weight gain and glucose regulation during antipsychotic drug treatment. Sussman, Suppl 23, 3–4
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Kinon, Feb 92–100
Mechanisms of antipsychotic-induced weight gain. McIntyre, Suppl 23, 23–29
Metformin in obesity associated with antipsychotic drug administration: a pilot study [letter]. Baptista, Aug 653–655
Pharmacology of weight gain with antipsychotics. Casey, Suppl 7, 4–10
Review of atypical antipsychotics and weight gain. Sussman, Suppl 23, 5–12
Weight change and atypical antipsychotic treatment in patients with schizophrenia. Jones B, Suppl 2, 41–44
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. Simpson MM, Sept 694–700
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Cohen S, Feb 114–116
Why do young women diet? the roles of body fat, body perception, and body ideal [CME]. Gruber, Aug 609–611
Women
Effects of the menstrual cycle on measures of personality in women with premenstrual syndrome: a preliminary study. Berlin, May 337–342
Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. Ahokas, May 332–336
Evaluation and management of depression in women across the life span. Kornstein, Suppl 24, 11–17
Mood disorder history and personality assessment in premenstrual dysphoric disorder. Critchlow, Sept 688–693
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Zanarini, Nov 849–854
Open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Lam RW, Mar 164–168
Prevention of recurrent postpartum depression: a randomized clinical trial. Wisner, Feb 82–86
Serum fluvoxamine levels in breastfed infants. Piontek, Feb 111–113
Venlafaxine in the treatment of postpartum depression. Cohen LS, Aug 592–596
Why do young women diet? the roles of body fat, body perception, and body ideal [CME]. Gruber, Aug 609–611
Women and traumatic events. Foa, Suppl 17, 29–34
Ziprasidone
Apparent effects of ziprasidone on plasma lipids and glucose. Kingsbury, May 347–349
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Lesem, Jan 12–18; Correction, Mar 209

Journal of Clinical Psychiatry

Author Index to Volume 62: January 2001 Through December 2001

Ablon JS see Cohen LS
Abouesh AI see Clayton AH
Adams LF see Berlin RE
Agarwal V, Kumar P. Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases [letter]. Apr 298–299
Agid O, Shalev AY, Lerer B. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. Mar 169–173
Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. May 332–336
Ahrén B see Hägg S
Aito M see Ahokas A
Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. July 541–544
Alarcón RD. Review of Cloninger CR (ed): *Personality and Psychopathology.* Apr 300–301
Alarcon RD see Rothbaum BO
Albert M see Tondo L
Albert SM see Schneier FR
Albertini RS see Phillips KA
Alessandrini ES see Janson MP
Allen A see Hollander E
Allen MH see Sachs GS
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. Suppl 7, 22–31
Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy [CME]. July 535–540
Altshuler A see Bloch Y
Altshuler KZ see Suppes T
Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J. Impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. Aug 612–616
Amann B see Grunze HCR
Andersen A see Bowers WA
Anderson T see Chengappa KNR
Andrade C, Srihari BS. Preliminary survey of rhinotillexomania in an adolescent sample. June 426–431
Andrade C, Srihari BS, Reddy KP, Chandramma L. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. Jan 41–45
Andrade E see Citrome L
Anton RF. Pharmacologic approaches to the management of alcoholism. Suppl 20, 11–17
Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen O-P, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. June 448–452
Arató M. Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder [letter]. Aug 657–658
Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. Suppl 23, 13–22
Ascher JA see Weihs KL
Atiullah N, Phillips KA. Fatal body dysmorphic disorder by proxy [letter]. Mar 204–205
Atzert R see Chengappa KNR
Austin M-P see Gladstone GL; Mitchell PB
Baca-García E, Diaz-Sastre C, Basurte E, Prieto R, Ceverino A, Saiz-Ruiz J, de Leon J. Prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. July 560–564
Baer L see Keuthen NJ
Baghai TC see Zwanzger P
Baker SM see Trivedi MH
Bakish D. New standard of depression treatment: remission and full recovery. Suppl 26, 5–9
Baldessarini RJ see Ghaemi SN
Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, O'Brien J. One-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments [CME]. Aug 631–636
Ballard CG, O'Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. Natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. Jan 46–49
Ballenger JC. Introduction: focus on generalized anxiety disorder. Suppl 11, 3
Ballenger JC. Introduction: focus on transcultural issues in depression and anxiety. Suppl 13, 3
Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. Suppl 19, 11–19
Ballenger JC. Treatment of anxiety disorders to remission. Suppl 12, 5–9
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen H-U. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Suppl 11, 53–58
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Jones RD, Berard RMF. Consensus statement on depression, anxiety, and oncology. Suppl 8, 64–67
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ (International Consensus Group on Depression and Anxiety), Kirmayer LJ, Lépine J-P, Lin K-M, Tajima O, Ono Y. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. Suppl 13, 47–55
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Lydiard RB, Mayer EA. Consensus statement on depression, anxiety, and functional gastrointestinal disorders. Suppl 8, 48–51
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Roose SP, Sheps DS. Consensus statement on depression, anxiety, and cardiovascular disease. Suppl 8, 24–27
Baptista T, Beaulieu S. Body weight gain, insulin, and leptin in olanzapine-treated patients [letter with reply]. Nov 902–903
Baptista T, Hernàndez L, Prieto LA, Boyero EC, de Mendoza S. Metformin in obesity associated with antipsychotic drug administration: a pilot study [letter]. Aug 653–655
Baral I see Price BH
Barnes LF see Schneier FR
Bartolucci G see Fava GA
Baruch Y see Chelben J
Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic–induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Suppl 23, 45–66
Basile VS see McIntyre RS
Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Apr 231–238
Basson BR see Jones B; Kinon BJ
Basurte E see Baca-García E
Batey SR see Weihs KL
Beasley CM Jr see Czekalla J
Beaulieu S see Baptista T
Bedair HS see Chen NC

Bégin S see Karagianis JL
Begley AE see Mulsant BH
Bellew KM see Pollack MH
Belmaker RH see Dossenbach MRK
Benabarre A see Colom F; Vieta E
Benazzi F. High prevalence of bipolar spectrum disorders [letter with reply]. Sept 735–736
Benca RM. Consequences of insomnia and its therapies. Suppl 10, 33–38
Benedek DM see Grieger TA
Berard RMF. Depression and anxiety in oncology: the psychiatrist's perspective. Suppl 8, 58–61
Berard RMF see Ballenger JC
Berg PH see Czekalla J
Berger M see Hajak G
Berkowitz HL. Thiazide diuretics and lithium levels [letter]. Jan 57
Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. Suppl 17, 60–63
Berlin RE, Raju JD, Schmidt PJ, Adams LF, Rubinow DR. Effects of the menstrual cycle on measures of personality in women with premenstrual syndrome: a preliminary study. May 337–342
Bernet W. Review of American Psychiatric Association: *Psychiatric Services in Jails and Prisons: A Task Force Report of the American Psychiatric Association, 2nd ed.* Aug 662
Bertino JS Jr see Nafziger AN
Bhandari S, Samellas D. Bipolar affective disorder and idiopathic pulmonary fibrosis [letter]. July 574–575
Biederman J see Wozniak J
Bienstock CA see Hollander E
Bikoff J see Sussman N
Bingham CR see Sajatovic M
Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. Suppl 15, 12–17
Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. Suppl 4, 7–11
Blier P see Leon AC
Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. Suppl 7, 11–21
Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? [CME] Nov 855–859
Blow FC see Valenstein M
Boerner RJ see Zwanzger P
Bogenschutz MP, Quinn DK. Acronyms for substance use disorders [letter]. June 474–475
Bolden-Watson C see Trivedi MH
Bond AJ see Critchlow DG
Borba CP see Henderson DC
Borian F see Ferguson JM
Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. Suppl 11, 37–42
Borkovec TD see Ballenger JC
Bouffard SM see Cohen LS
Boulanger B see Demyttenaere K
Bowden CL. Introduction: role of anticonvulsants as mood stabilizers. Suppl 14, 3–4
Bowden CL see Calabrese JR
Bowers MB Jr see Chen NC; Preda A
Bowers WA, Andersen A. Review of Lock J, Le Grange D, Agras WS, Dare C: *Treatment Manual for Anorexia Nervosa: A Family-Based Approach.* Oct 831
Boyero EC see Baptista T
Brady KT see Myrick H
Brar JS see Chengappa KNR
Brault Y see Meoni P
Breier A. Introduction: a new era in the pharmacotherapy of psychotic disorders. Suppl 2, 3–5
Breier A see Clark WS
Brescan DW see Sajatovic M
Breslau N. Epidemiology of posttraumatic stress disorder: what is the extent of the problem? Suppl 17, 16–22
Breslau N. Outcomes of posttraumatic stress disorder. Suppl 17, 55–59
Brismar K see Melkersson K
Brooks BA. Review of Cepeda C: *Concise Guide to the Psychiatric Interview of Children and Adolescents.* Feb 131
Brooks BA. Review of Meeks JE, Bernet W: *The Fragile Alliance: An Orientation to Psychotherapy of the Adolescent, 5th ed.* June 482–483
Brown LL see Shelton RC
Bruce SE see Salzman C
Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Jan 50–56
Bruun RD see Budman CL
Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. Open-label study of the treatment efficacy of olanzapine for Tourette's disorder. Apr 290–294
Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CTM. Randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Apr 239–248
Buitelaar JK see Bruggeman R; Kooij JJS
Bullock D see Pyne JM
Burdick KE see Goldberg JF
Burke WJ, McArthur-Miller DA. Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. Suppl 22, 38–42
Burnham DB see Pollack MH
Bystritsky A see Saxena S
Caban SJ see Calabrese JR
Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, Kimmel SE, Caban SJ. Bipolar rapid cycling: focus on depression as its hallmark. Suppl 14, 34–41
Calcagno J see Altshuler L
Calil HM. Fluoxetine: a suitable long-term treatment. Suppl 22, 24–29
Campbell EC see Caroff SN
Cao LY see Zhang XY
Carmody TJ see Trivedi MH
Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: a pilot study. Oct 772–775
Caroff SN, Campbell EC, Havey JC, Sullivan KA, Katz IR, Mann SC. Treatment of tardive dyskinesia with donepezil [letter]. Feb 128–129
Cartwright C see Hollander E
Caruso KA. Review of Wear-Finkle DJ: *Medicolegal Issues in Clinical Practice: A Primer for the Legally Challenged.* Aug 659–660
Casey DE. Clinical trial design issues in schizophrenic research. Suppl 9, 17–20
Casey DE, Zorn SH. Pharmacology of weight gain with antipsychotics. Suppl 7, 4–10
Casey DE see Allison DB
Cassano GB see Ciapparelli A
Cassem EH see Price BH
Ceverino A see Baca-García E
Chandramma L see Andrade C
Chang W-H see Lane H-Y
Chang Y-C see Lane H-Y
Charney DA, Paraherakis AM, Gill KJ. Integrated treatment of comorbid depression and substance use disorders. Sept 672–677
Chelben J, Strous RD, Lustig M, Baruch Y. Remission of SSRI-induced akathisia after switch to nefazodone [letter]. July 570–571
Chen J-Y see Lane H-Y
Chen N see Davis JM
Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. June 479–480
Chengappa KNR, Kambhampati RK, Perkins K, Nigam R, Anderson T, Brar JS, Vemulapalli HK, Atzert R, Key P, Kang JS, Levine J. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. July 503–508
Chengappa KNR see Kupfer DJ
Chiavacci MC see Ciapparelli A
Chiu C-C see Lane H-Y
Ciapparelli A, Dell'Osso L, Tundo A, Pini S, Chiavacci MC, Di Sacco I, Cassano GB. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. July 552–555
Citrome L, Krakowski M, Greenberg WM, Andrade E, Volavka J. Antiaggressive effect of quetiapine in a patient with schizoaffective disorder [letter]. Nov 901
Clark WS, Street JS, Feldman PD, Breier A. Effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Jan 34–40
Clary CM see Roy-Byrne PP
Clayton AH. Recognition and assessment of sexual dysfunction associated with depression. Suppl 3, 5–9
Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. Mar 185–190
Cochiolo JA see Parris C
Cohen-Kettenis P see Buitelaar JK

Cohen LS, Viguera AC, Bouffard SM, Nonacs RM, Morabito C, Collins MH, Ablon JS. Venlafaxine in the treatment of postpartum depression. Aug 592–596
Cohen M see Fava M
Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Feb 114–116
Cohrs S see Hajak G
Colla M see Lederbogen F
Collins MH see Cohen LS
Colom F, Vieta E, Benabarre A, Martínez-Arán A, Reinares M, Corbella B, Gastó C. Topiramate abuse in a bipolar patient with an eating disorder [letter]. June 475–476
Colom F see Vieta E
Colucci SV see Roy-Byrne PP
Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. May 362–366
Conley RR. Evaluating clinical trial data: outcome measures. Suppl 9, 23–26
Connolly CE see Henderson DC
Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents [CME]. Dec 967–974
Copeland LA see Valenstein M
Corbella B see Colom F; Vieta E
Cornelius JD see Thase ME
Cosgrove GR see Price BH
Coupland NJ. Social phobia: etiology, neurobiology, and treatment. Suppl 1, 25–35
Craske M see Mayer EA
Crawford AMK see Gomez J-C; Jones B
Crawford SG see Kaplan BJ
Crisham KP see Dennis JL
Crismon ML see Suppes T
Critchlow DG, Bond AJ, Wingrove J. Mood disorder history and personality assessment in premenstrual dysphoric disorder. Sept 688–693
Croker VM see Sachdev PS
Crow SJ see Grant JE
Crowder MK. Review of Rudd MD, Joiner T, Rajab MH: *Treating Suicidal Behavior: An Effective, Time-Limited Approach.* Dec 996–997
Crystal S see Walkup J
Culpepper L. Early onset of antidepressant action: impact on primary care. Suppl 4, 4–6
Culpepper L see Leon AC
Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Mar 153–157
Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. Suppl 5, 10–13
Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Mar 191–198
Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Suppl 2, 35–40
David AS see Sierra M
Davidson JRT. Introduction: advances and emerging treatments in social phobia. Suppl 1, 4
Davidson JRT. Pharmacotherapy of generalized anxiety disorder. Suppl 11, 46–50
Davidson JRT see Ballenger JC; Rabinowitz J
Davidson M. Long-term safety of risperidone. Suppl 21, 26–28
Davis JM, Chen N. Effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and International trials. Oct 757–771
Dawe IC see Karagianis JL
Deaciuc SC see Zisook S
De Bie J see Demyttenaere K
DeCecco LM see Nierenberg AA
Deckersbach T see Keuthen NJ
De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. Suppl 21, 19–22
DeGraw JD see Shapira NA
de Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients [letter]. Feb 129–130
de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. Suppl 22, 43–47
de Leon J see Baca-García E
de León J see López P
Dell'Osso L see Ciapparelli A
Dellva MA see Czekalla J
de Mendoza S see Baptista T
Dempfle C-E see Lederbogen F
Demyttenaere K, Enzlin P, Dewé W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. Suppl 22, 30–33
Demyttenaere K, Enzlin P, Dewé W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. Suppl 22, 34–37
Dennehy EB see Suppes T
Dennis JL, Crisham KP. Chronic assaultive behavior improved with sleep apnea treatment [letter]. July 571–572
De Troyer W see Demyttenaere K
Deuschle M see Lederbogen F
Devlin MJ see Simpson MM
Dewé W see Demyttenaere K
Diaz-Sastre C see Baca-García E
Dierker LC, Merikangas KR. Familial psychiatric illness and posttraumatic stress disorder: findings from a family study of substance abuse and anxiety disorders [CME]. Sept 715–720
DiGiovanni SK see Sajatovic M
Dillingham K see Tucker P
Dinan TG. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. Suppl 22, 48–52
Di Sacco I see Ciapparelli A
Docherty JP. Interpretations and conclusions in the clinical trial. Suppl 9, 40–43
Doghramji PP. Detection of insomnia in primary care. Suppl 10, 18–26. Correction, Aug 658
Dolgoff-Kaspar R see Hollander E
Donahue RMJ see Trivedi MH; Weihs KL
Doraiswamy PM. Contemporary management of comorbid anxiety and depression in geriatric patients. Suppl 12, 30–35
Doraiswamy PM see Van Meter SA
Dossenbach MRK, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Suppl 2, 28–34
Dossenbach MRK see Marténvi F
Dougherty DD see Keuthen NJ
Dunkin JJ see Saxena S
Dunner DL. Acute and maintenance treatment of chronic depression. Suppl 6, 10–16
Dunner DL see Fava M
Dwight MM see Phillips KA
Ebert MH. Review of Appleton WS: *Prozac and the New Antidepressants, revised ed.: What You Need to Know About Prozac, Zoloft, Paxil, Luvox, Wellbutrin, Effexor, Serzone, Vestra, Celexa, St. John's Wort, and Others.* Mar 210
Ebert MH. Review of Weissman S, Sabshin M, Eist H (eds): *Psychiatry in the New Millennium.* Sept 737
Einat H see Itkin O
Eisen JL see Phillips KA
El-Mallakh R see Janson MP
Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder [CME]. June 486–491
Enns MW. Seizure during combination of trimipramine and bupropion [letter]. June 476–477
Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Nov 869–877
Enzlin P see Demyttenaere K
Ereshefsky L, Glazer WM. Conclusion: comparison of the bioequivalence of generic versus branded clozapine. Suppl 5, 27–27
Ereshefsky L, Meyer MC. Introduction: comparison of the bioequivalence of generic versus branded clozapine. Suppl 5, 3
Ereshefsky L see Lam YWF
Erman MK. Sleep architecture and its relationship to insomnia. Suppl 10, 9–17
Ertl MG see Rainer MK
Eyers K see Gladstone GL
Ezcurra J see López P
Farfel GM see Londborg PD
Farnsworth MG see Kluznik JC
Fava GA, Bartolucci G, Rafanelli C, Mangelli L. Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. July 556–559
Fava M. Augmentation and combination strategies in treatment-resistant depression. Suppl 18, 4–11
Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. June 413–420
Fayek M see Kingsbury SJ
Feighner JP see Thase ME
Feldman PD see Clark WS
Fennig S see Bloch Y

Ferguson JM. Effects of antidepressants on sexual functioning in depressed patients: a review. Suppl 3, 22–34
Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Jan 24–29
Fernández A see Vieta E
Ferre RC see Kaplan BJ
Ferrier IN. Characterizing the ideal antidepressant therapy to achieve remission. Suppl 26, 10–15
Findling RL. Review of Kushner HI: *A Cursing Brain? The Histories of Tourette Syndrome.* July 578
Findling RL. Review of Rapoport JL (ed): *Childhood Onset of "Adult" Psychopathology: Clinical and Research Advances.* Feb 132
Findling RL see Wisner KL
Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. Suppl 21, 3–6
Fisher CB see Pearson JL
Fleischhacker WW see Kurzthaler I; Meltzer HY
Fletcher KE see Connor DF
Flynn J see Grieger TA
Flynn T see Mulsant BH
Foa EB, Street GP. Women and traumatic events. Suppl 17, 29–34
Fossey J see Ballard CG
Fraim C see Keuthen NJ
Frangou S see Lewis M
Frank E, Judge R. Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. Suppl 22, 10–15
Frank E, Kupfer DJ, Gerebtzoff A, Meya U, Laghrissi-Thode F, Grochocinski VJ, Houck PR, Mallinger AG, Gibbons RD. Development of study exit criteria for evaluating antimanic compounds. June 421–425
Frank E see Melhem NM
Frankenburg FR see Zanarini MC
Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. Suppl 12, 16–23
Freeman AM. Review of Frank E (ed): *Gender and Its Effects on Psychopathology.* June 481–482
Freeman AM III. Review of Foa EB, Keane TM, Friedman MJ (eds): *Effective Treatments for PTSD: Practice Guidelines From the International Society for Traumatic Stress Studies.* Nov 905
Friedman ES see Thase ME
Frye M see Altshuler L
Gallop R see Caroff SN
García-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder [letter]. June 474
Garno JL see Goldberg JF
Gastó C see Colom F; Navarro V; Vieta E
Gay VP. Review of Shorto R, Holt H: *Saints and Madmen: Psychiatry Opens Its Doors to Religion.* Apr 301–302
Gayer A see Budman CL
Gelenberg AJ. Grow the market [commentary]. Aug 589
Gelenberg AJ. Many thanks. Jan 3–5
Gelenberg AJ see Kupfer DJ
Geller PA, Klier CM, Neugebauer R. Anxiety disorders following miscarriage. June 432–438
Gerebtzoff A see Frank E
Gericke GS see Bruggeman R
Gersh T see Silvestri R
Ghaemi SN. Reply to Benazzi F: High prevalence of bipolar spectrum disorders [letter]. Sept 735–736
Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. July 565–569
Ghiani C see Tondo L
Gibbons RD see Frank E
Gibson PJ see Sanger TM
Gil-Ad I see Aizenberg D
Gill KJ see Charney DA
Gillin JC, Smith-Vaniz A, Schnierow B, Rapaport MH, Kelsoe J, Raimo E, Marler MR, Goyette LM, Stein MB, Zisook S. Open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. Oct 789–796
Gillin JC see Patten CA; Pyne JM
Gilmore JA see Basson BR; Kinon BJ
Gindre C see Henry C
Ginsberg DL see Sussman N
Gitlin M see Altshuler L
Gladstone GL, Mitchell PB, Parker G, Wilhelm K, Austin M-P, Eyers K. Indicators of suicide over 10 years in a specialist mood disorders unit sample. Dec 945–951
Glazer WM see Ereshefsky L
Glazewski R see Cohen S
Goddard A see Pollack MH
Godemann F see Jockers-Scherübl MC
Goetz RR see Simpson MM
Goetz SA see Simpson MM
Goff DC see Henderson DC
Goikolea JM see Vieta E
Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. Suppl 14, 27–33
Goldberg JF, Singer TM, Garno JL. Suicidality and substance abuse in affective disorders. Suppl 25, 35–43
Goldberg JF see Kupfer DJ
Goldenberg I see Salzman C
Goldstein D see Londborg PD
Goldstein S see Londborg PD
Golshan S see Patten CA; Pyne JM
Gomez J-C, Crawford AMK. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Suppl 2, 6–11
Gómez JC see Sacristán JA
Gonzales C see Lam YWF
González-Pinto A see López P
Goodman R see Altshuler L
Gorman CP see Kaplan BJ
Gorman JM see Leon AC; Stahl SM
Goss-Bley AI see Nafziger AN
Goyette LM see Gillin JC
Graap K see Rothbaum BO
Grace JL see Narendran R
Grandin LD, Yan LJ, Gray SM, Jamison KR, Sachs GS. Suicide prevention: increasing education and awareness. Suppl 25, 12–16
Grandin LD see Nierenberg AA
Grant JE. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report [letter]. Apr 297
Grant JE, Kim SW. Demographic and clinical features of 131 adult pathological gamblers. Dec 957–962
Grant JE, Kim SW, Crow SJ. Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. July 517–522
Graves JB see Matuschka PR
Gray SM, Otto MW. Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. Suppl 25, 56–64
Gray SM see Grandin LD; Nierenberg AA
Greaney MG see Sanger TM
Greden JF. Burden of disease for treatment-resistant depression. Suppl 16, 26–31
Greden JF. Burden of recurrent depression: causes, consequences, and future prospects. Suppl 22, 5–9
Greenberg WM see Citrome L
Greist JH see Fava M; Katzelnick DJ
Grewal A see Lam RW
Grieger TA, Benedek DM, Flynn J. Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder [letter]. Jan 59–60
Grochocinski VJ see Frank E; Kupfer DJ
Grossman R see Hollander E
Gruber AJ, Pope HG Jr, Lalonde JK, Hudson JI. Why do young women diet? the roles of body fat, body perception, and body ideal [CME]. Aug 609–611
Grudzinski AN see Roy-Byrne PP
Grundy SL see Czekalla J; Dossenbach MRK; Sanger TM
Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study [CME]. May 394–399. Correction, June 480
Grunze HCR, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindienst N, Walden J. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. June 464–468
Gutiérrez M see López P
Habermacher ED see Suppes T
Hackett D see Meoni P
Hagerty BM. Changing paradigms: depressed patients as treatment partners [letter]. June 478–479
Hägg S, Söderberg S, Ahrén B, Olsson T, Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. Nov 843–848
Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. June 453–463

Hanson CA see Krahn LE
Hanusa BH see Wisner KL
Harmon RJ. Review of Bradley SJ: *Affect Regulation and the Development of Psychopathology.* June 481
Harrigan EP see Lesem MD
Hartford JT see Ferguson JM
Harvey BH see Seedat S
Hattab H see Sajatovic M
Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. Suppl 27, 15–26
Haushofer M see Rainer MK
Havey JC see Caroff SN
Hawkridge SM see Bruggeman R
Hayden D see Henderson DC
Heaton RK see Jin H
Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. Suppl 14, 22–26
Heck AH see de Groot IW
Hedges DW see Reimherr FW
Hegel MT see Londborg PD
Heimberg RG. Current status of psychotherapeutic interventions for social phobia. Suppl 1, 36–42
Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. Suppl 27, 10–14
Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. Suppl 23, 39–44
Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. Risperidone added to clozapine: impact on serum prolactin levels. Aug 605–608
Henderson S see Myrick H
Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors. Apr 249–255
Hernàndez L see Baptista T
Herraiz M see Vieta E
Heuser I see Lederbogen F
Hill AL see Kinon BJ
Hilligoss NM see Littrell KH
Himmelhoch JM see Londborg PD
Hirschfeld RMA. Bipolar spectrum disorder: improving its recognition and diagnosis. Suppl 14, 5–9
Hirschfeld RMA see Kupfer DJ; Leon AC
Hobson JA see Silvestri R
Hodges LF see Rothbaum BO
Hohagen F see Hajak G
Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ. Preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Mar 199–203
Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. Open trial of divalproex sodium in autism spectrum disorders. July 530–534
Holsboer F see Wittchen H-U
Hopko DR, Averill PM, Small D, Greenlee H, Varner RV. Use of the Brief Psychiatric Rating Scale to facilitate differential diagnosis at acute inpatient admission [CME]. Apr 304–312
Horiguchi J see Miyaoka T
Hornik T see Rabinowitz J
Houck PR see Frank E; Kupfer DJ
Hough DW. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder [letter]. Apr 296–297
Houser TL see Trivedi MH; Weihs KL
Howland RH see Thase ME
Hoyer J see Wittchen H-U
Huang H see Entsuah AR
Huang M-C see Lane H-Y
Hudson JI see Gruber AJ
Hulting A-L see Melkersson K
Ieni J see Ferguson JM
Ihde-Scholl T, Jefferson JW. Mirtazapine-associated palinopsia [letter]. May 373
Inagaki T see Miyaoka T
Isometsä ET see Rytsälä HJ
Itkin O, Nemets B, Einat H. Smoking habits in bipolar and schizophrenic outpatients in southern Israel. Apr 269–272
Itoga M see Miyaoka T
Iyengar MK see Pollack MH
Izquierdo JA see Montejo AL
Jackson CW see Markowitz JS
Jacobi F see Wittchen H-U
Jamison KR see Grandin LD
Jann MW see Lane H-Y
Janson MP, Alessandrini ES, Strunjas SS, Shahab H, El-Mallakh R, Lippmann SB. Internet-observed suicide attempts [letter]. June 478
Jefferson JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). Suppl 1, 50–53
Jefferson JW see Ihde-Scholl T
Jenike MA see Keuthen NJ; Price BH
Jeste DV see Jin H
Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients [CME]. Oct 797–803
Jockers-Scherübl MC, Godemann F, Pietzcker A. Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study [letter]. July 573
Jody D see Ferguson JM
Johnson CG see Littrell KH
Jones B, Basson BR, Walker DJ, Crawford AMK, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. Suppl 2, 41–44
Jones B, Taylor CC, Meehan K. Efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Suppl 2, 22–24
Jones BN. Review of Salzman C: *Psychiatric Medication for Older Adults: The Concise Guide.* Sept 739
Jones RD. Depression and anxiety in oncology: the oncologist's perspective. Suppl 8, 52–55
Jones RD see Ballenger JC
Judge R. Patient perspectives on once-weekly fluoxetine. Suppl 22, 53–57
Judge R see Frank E
Kambhampati RK see Chengappa KNR
Kane JM. Dose selection and comparator drugs in schizophrenia research. Suppl 9, 29–32
Kang JS see Chengappa KNR
Kaplan BJ, Simpson JSA, Ferre RC, Gorman CP, McMullen DM, Crawford SG. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. Dec 936–944
Kaplan RM see Pyne JM
Karageorge J see Melhem NM
Karagianis JL, Dawe IC, Thakur A, Bégin S, Raskin J, Roychowdhury SM, for the Acute Setting Agitation Program (ASAP) Study Group. Rapid tranquilization with olanzapine in acute psychosis: a case series. Suppl 2, 12–16
Kashuba ADM see Nafziger AN
Katz IR see Caroff SN
Katzelnick DJ, Greist JH. Social anxiety disorder: an unrecognized problem in primary care. Suppl 1, 11–15
Kaukoranta J see Ahokas A
Keck PE Jr see Nelson EB
Keith SJ. Evaluating characteristics of patient selection and dropout rates. Suppl 9, 11–14
Keller MB. Long-term treatment of recurrent and chronic depression. Suppl 24, 3–5
Keller MB see Salzman C; Thase ME
Kelsey JE. Clinician perspective on achieving and maintaining remission in depression. Suppl 26, 16–21
Kelsoe JR see Gillin JC; Patten CA; Pyne JM
Kennedy JL see Basile VS
Keuthen NJ, Fraim C, Deckersbach T, Dougherty DD, Baer L, Jenike MA. Longitudinal follow-up of naturalistic treatment outcome in patients with trichotillomania. Feb 101–107
Key P see Chengappa KNR
Khan A see Cohen S; Phillips KA
Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone [letter]. May 375–376
Khan S see Cohen S
Kim CH see Zeng S
Kim SW see Grant JE
Kim YS see Lyoo IK
Kimmel SE see Calabrese JR
King CA see Pearson JL
Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. Apparent effects of ziprasidone on plasma lipids and glucose. May 347–349
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Feb 92–100
Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Suppl 2, 17–21
Kinon BJ see Basson BR; Jones B
Kiriakos L see Altshuler L
Kirmayer LJ. Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. Suppl 13, 22–28
Kirmayer LJ see Ballenger JC
Kleiber BA see Trivedi MH
Klein RM see Walker JB

Kleindienst N see Grunze HCR
Klier CM see Geller PA
Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. Suppl 5, 14–17
Knoke DM see Naranjo CA
Kolar AB see Kupfer DJ
Kollack-Walker S see Czekalla J
Kong SW see Lyoo IK
Kooij JJS, Middelkoop HAM, van Gils K, Buitelaar JK. Effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. Dec 952–956
Kornstein SG. Evaluation and management of depression in women across the life span. Suppl 24, 11–17
Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. Suppl 16, 18–25
Koskinen TE see Appelberg BG
Kotteda V see Malla AK
Krahn LE, Hanson CA, Pileggi TS, Rummans TA. Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. Feb 108–110
Krakowski M see Citrome L
Kratky P see Dossenbach MRK
Kraxberger E see Rainer MK
Kremer C see Quitkin FM
Krystal JH see Sierra M
Kumar P see Agarwal V
Kumar S, Oakley-Browne M. Problems with ensuring a double blind [letter with reply]. Apr 295–296
Kupfer DJ. Introduction: role of enteric-coated fluoxetine once-weekly in achieving optimal outcomes in the long-term treatment of depression. Suppl 22, 3–4
Kupfer DJ, Chengappa KNR, Gelenberg AJ, Hirschfeld RMA, Goldberg JF, Sachs GS, Grochocinski VJ, Houck PR, Kolar AB. Citalopram as adjunctive therapy in bipolar depression. Dec 985–990
Kupfer DJ see Frank E
Kuroda S see Wada K
Kurzthaler I, Fleischhacker WW. Clinical implications of weight gain in schizophrenia. Suppl 7, 32–37
Kwentus JA. Review of Work Group on Delirium of the American Psychiatric Association: *Practice Guidelines for the Treatment of Patients With Delirium.* Jan 64
Kwon JS see Lyoo IK
Lacoste J see Henry C
Laghrissi-Thode F see Frank E
Lalonde JK see Gruber AJ
Lam RW, Lee SK, Tam EM, Grewal A, Yatham LN. Open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. Mar 164–168
Lam RW see Miller DS
Lam YWF, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. Suppl 5, 18–22
Lambert MV see Sierra M
Lamberti JS see Seger A
Lamps CA. Review of Davidson JRT, Connor KM: *Herbs for the Mind: What Science Tells Us About Nature's Remedies for Depression, Stress, Memory Loss, and Insomnia.* Sept 738–739
Lamps CA. Review of Tomb DA: *Psychiatry (House Officer Series, 6th ed.)* Jan 64–65
Landa A see Aizenberg D
Lane H-Y, Chang W-H, Chiu C-C, Huang M-C, Lee S-H, Chen J-Y. Pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia [letter]. Dec 994–995
Lane H-Y, Jann MW, Chang Y-C, Chiu C-C, Huang M-C, Lee S-H, Chang W-H. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. Oct 812–817
Lang AJ, Stein MB. Social phobia: prevalence and diagnostic threshold. Suppl 1, 5–10
Langosch J see Grunze HCR
Lara DR, Souza DO. Should we keep calling antidepressants *antidepressants*? [letter with reply] Oct 829
Lavin PJM. Review of Evans RW, Mathew NT: *Handbook of Headache.* Aug 660–661
Lazarus A. Physical restraints, thromboembolism, and death in 2 patients [letter]. Mar 207–208
Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. Suppl 27, 5–9
Leboyer M see Henry C
Lecrubier Y. Burden of depression and anxiety in general medicine. Suppl 8, 4–9
Lecrubier Y. Prescribing patterns for depression and anxiety worldwide. Suppl 13, 31–36
Lecrubier Y see Ballenger JC
Lederbogen F, Weber B, Colla M, Heuser I, Deuschle M, Dempfle C-E. Antidepressant treatment and global tests of coagulation and fibrinolysis [letter]. Feb 130
Lee DW see Lyoo IK
Lee S-H see Lane H-Y
Lee SK see Lam RW
Lee Y see Wada K
Lenox MS see Ghaemi SN
Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. Suppl 4, 12–16
Leon AC, Blier P, Culpepper L, Gorman JM, Hirschfeld RMA, Nierenberg AA, Roose SP, Rosenbaum JF, Stahl SM, Trivedi MH. Ideal trial to test differential onset of antidepressant effect. Suppl 4, 34–36
Lépine J-P. Epidemiology, burden, and disability in depression and anxiety. Suppl 13, 4–10
Lépine J-P see Ballenger JC
Lerer B see Agid O
Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Jan 12–18; Correction, Mar 209
Leskelä US see Rytsälä HJ
Lesser M see Budman CL
Lestelä-Mielonen PS see Rytsälä HJ
Levine J see Chengappa KNR
Lewis LJ. Consumer perspective of diagnosis and treatment of chronic major depression. Suppl 6, 30–34
Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. Oct 749–756
Lieberman JA. Hypothesis and hypothesis testing in the clinical trial. Suppl 9, 5–8
Lieberman JA see Basile VS
Lin K-M. Biological differences in depression and anxiety across races and ethnic groups. Suppl 13, 13–19
Lin K-M see Ballenger JC
Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. Suppl 23, 30–38
Lippmann SB see Janson MP
Littrell KH, Petty RG, Peabody CD, Hilligoss NM, Johnson CG. Treatment of preexisting diabetes with olanzapine [letter]. Sept 733–734
Llorca G see Montejo AL
Lomax JW. Review of Bloom JD, Nadelson CC, Notman MT (eds): *Physician Sexual Misconduct.* Sept 738
Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. May 325–331
Loo CK see Sachdev PS
López P, Mosquera F, de León J, Gutiérrez M, Ezcurra J, Ramírez F, González-Pinto A. Suicide attempts in bipolar patients. Dec 963–966
Lopez RP see Hollander E
Louis ED see Schneier FR
Lustig M see Chelben J
Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? Suppl 8, 38–45
Lydiard RB. Social anxiety disorder: comorbidity and its implications. Suppl 1, 17–23
Lydiard RB see Ballenger JC; Thase ME
Lyoo IK, Lee DW, Kim YS, Kong SW, Kwon JS. Patterns of temperament and character in subjects with obsessive-compulsive disorder. Aug 637–641
Mack JM see Parris C
MacLean RW see Preda A
Maddock R see Londborg PD
Mahendran R. Clozapine in the treatment of hypomania with neurosyphilis [letter]. June 477–478
Maidment K see Saxena S
Malcolm R see Myrick H
Malhi GS see Mitchell PB; Sachdev PS
Malla AK, Norman RMG, Scholten DJ, Zirul S, Kotteda V. Comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Mar 179–184
Mallinger AG see Frank E
Mancini DA see McIntyre RS
Mangelli L see Fava GA
Mann JI see Elmslie JL
Mann JJ see Oquendo MA
Mann SC see Caroff SN
Marangell LB. Switching antidepressants for treatment-resistant major depression. Suppl 18, 13–17

Marchant BK see Reimherr FW
Marcuse A see Zwanzger P
Margallo-Lana M see Ballard CG
Markowitz JS, McLeod-Bryant S, Jackson CW. Cost savings with intramuscular anticholinergics [letter]. Apr 295
Marler MR see Gillin JC
Marténvi F, Metcalfe S, Schausberger B, Dossenbach MRK. Efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. Suppl 2, 25–27
Martínez G see Vieta E
Martínez-Arán A see Colom F; Vieta E
Masand PS. Olanzapine versus other antipsychotics in the treatment of schizophrenia [letter with reply]. Oct 828
Masching AJ see Rainer MK
Masellis M see Basile VS
Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Suppl 20, 42–48
Mason M see Suppes T
Mataix-Cols D see Alonso P
Matthews SC, Miller BP. Auditory hallucinations associated with topiramate [letter]. Aug 653
Matuschka PR, Graves JB. Mean dose after splitting sertraline tablets [letter]. Oct 826
Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. Suppl 8, 28–36
Mayer EA see Ballenger JC
Mazumdar S see Mulsant BH
Mazure CM see Chen NC; Preda A
McArthur-Miller DA see Burke WJ
McBride R see Sachdev PS
McCafferty JP see Pollack MH
McCall WV. Psychiatric perspective on insomnia. Suppl 10, 27–32
McConville B see Silver AA
McCrone P see Lewis M
McElroy SL see Phillips KA
McGarvey EL see Clayton AH
McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. Suppl 23, 23–29
McIntyre RS see Basile VS
McKay B see Chen NC
McKeith IG see Ballard CG
McLendon B see Van Meter SA
McLeod-Bryant S see Markowitz JS
McMullen DM see Kaplan BJ
McQuade RD see Ferguson JM
Meehan K see Jones B
Mehtonen O-P see Appelberg BG
Melartin TK see Rytsälä HJ
Melhem NM, Rosales C, Karageorge J, Reynolds CF III, Frank E, Shear MK. Comorbidity of Axis I disorders in patients with traumatic grief. Nov 884–887
Melkersson K, Hulting A-L, Brismar K. Reply to Baptista T: Body weight gain, insulin, and leptin in olanzapine-treated patients [letter]. Nov 903–904
Melman CTM see Buitelaar JK
Melstrom K see Kluznik JC
Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. Suppl 27, 35–39
Meltzer HY, Fleischhacker WW. Introduction. Weight gain: a growing problem in schizophrenia management. Suppl 7, 3
Meltzer HY see Basile VS
Menchon JM see Alonso P
Mendelson WB. Neurotransmitters and sleep. Suppl 10, 5–8
Mendlovic S see Bloch Y
Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Nov 888–893
Merikangas KR see Dierker LC
Merkatz L see Hollander E
Mesters P see Demyttenaere K
Metcalfe S see Dossenbach MRK; Marténvi F
Metz A see Trivedi MH
Meya U see Frank E
Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. Suppl 27, 27–34
Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. Suppl 5, 4–9
Meyer MC see Ereshefsky L
Micallef J see Blin O
Miceli RJ see Roy-Byrne PP
Middelkoop HAM see Kooij JJS
Miller AH see Compton MT
Miller BP see Matthews SC
Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania [CME]. Dec 975–980
Milton DR see Kinon BJ
Minov C see Zwanzger P
Mintz J see Altshuler L
Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. Suppl 21, 23–25
Mitchell P see Parker G
Mitchell PB, Wilhelm K, Parker G, Austin M-P, Rutgers P, Malhi GS. Clinical features of bipolar depression: a comparison with matched major depressive disorder patients [CME]. Mar 212–216
Mitchell PB see Gladstone GL; Sachdev PS
Miyaoka T, Seno H, Itoga M, Ohshiro R, Inagaki T, Horiguchi J, Tachibana H. Chilaiditi syndrome–associated schizophrenia: 3 case reports [letter]. Jan 58–59
Miyaoka T, Seno H, Yamamori C, Inagaki T, Itoga M, Tsubouchi K, Horiguchi J. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. July 573–574
Mjörndal T see Hägg S
Modai I see Aizenberg D
Möller H-J see Zwanzger P
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F, for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Suppl 3, 10–21
Morabito C see Cohen LS
Mosquera F see López P
Muhonen TT see Appelberg BG
Mulsant BH, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, Begley AE, Mazumdar S, Reynolds CF III. Double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Aug 597–604
Myint P see Ballard CG
Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. Jan 19–23
Nafziger AN, Bertino JS Jr, Goss-Bley AI, Kashuba ADM. Reply to Waldinger MD: Sexual dysfunction and fluvoxamine therapy [letter]. Feb 127–128
Naliboff BD see Mayer EA
Namjoshi MA see Sanger TM
Naranjo CA, Knoke DM. Role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Suppl 20, 18–25
Narendran R, Young CM, Valenti AM, Pristach CA, Pato MT, Grace JL. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. July 509–516
Nash JL. Review of Gabbard GO: *Psychodynamic Psychiatry in Clinical Practice, 3rd ed.* Apr 302
Nathan A-M see Lindenmayer J-P
Naukkarinen HH see Appelberg BG
Navarro V, Vieta E, Gastó C. Mannitol-induced acute manic state [letter]. Feb 126
Neill D see Ballard CG
Nelson EB, Shah VN, Welge JA, Keck PE Jr. Placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction. June 469–473
Nelson JC. Diagnosing and treating depression in the elderly. Suppl 24, 18–22
Nelson SH. Review of Okasha A, Arboleda-Flórez J, Sartorius N (eds): *Ethics, Culture, and Society: International Perspectives.* Aug 661
Nemets B see Itkin O
Neugebauer R see Geller PA
Newcomer JW. Introduction: metabolic disturbances associated with antipsychotic use. Suppl 27, 3–4
Newcomer JW see Haupt DW
Nierenberg AA. Do some antidepressants work faster than others? Suppl 15, 22–25
Nierenberg AA. Long-term management of chronic depression. Suppl 6, 17–21
Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. Suppl 16, 5–9
Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. Suppl 25, 27–30
Nierenberg AA see Leon AC; Price BH; Stahl SM; Thase ME
Nigam R see Chengappa KNR
Ninan PT. Dissolving the burden of generalized anxiety disorder. Suppl 19, 5–10
Ninan PT. Introduction. Generalized anxiety disorder: why are we failing our patients? Suppl 19, 3–4
Nizny MM. Review of Allen JG: *Coping With Trauma: A Guide to Self-Understanding.* 2000;61:953–954; Correction, Mar 209
Nobler M see Roose SP
Nonacs RM see Cohen LS

Norman RMG see Malla AK
Normann C see Grunze HCR
Novotny S see Hollander E
Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. Suppl 11, 22–27
Nutt DJ see Ballenger JC
Oakley-Browne M see Kumar S
O'Brien CP. Introduction: pharmacologic treatment of alcohol abuse and addiction. Suppl 20, 3
O'Brien JT see Ballard CG
Ohshiro R see Miyaoka T
O'Leary D, Paykel E, Todd C, Vardulaki K. Suicide in primary affective disorders revisited: a systematic review by treatment era [CME]. Oct 804–811
Olfson M see Grunebaum MF
Olivier B see Waldinger MD
Olsson T see Hägg S
Ono Y see Ballenger JC
Oquendo MA, Mann JJ. Identifying and managing suicide risk in bipolar patients. Suppl 25, 31–34
Otto MW see Gray SM
Owen R see Valenstein M
Pace-Schott EF see Silvestri R
Padberg F see Zwanzger P
Palmer BW see Jin H
Pan J-Y see Trivedi MH
Panagides J see Thase ME
Paraherakis AM see Charney DA
Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. Feb 117–125
Parker G see Gladstone GL; Mitchell PB
Parris C, Mack JM, Cochiolo JA, Steinmann AF, Tietjen J. Hypothermia in 2 patients treated with atypical antipsychotic medication [letter]. Jan 61–63
Pato MT see Narendran R
Patten CA, Gillin JC, Golshan S, Wolter TD, Rapaport M, Kelsoe J. Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder. May 319–324
Patterson TL see Jin H
Patterson WM see Londborg PD
Paykel E see O'Leary D
Peabody CD see Littrell KH
Pearson JL, Stanley B, King CA, Fisher CB. Intervention research with persons at high risk for suicidality: safety and ethical considerations. Suppl 25, 17–26
Pedrelli P see Zisook S
Peindl KS see Piontek CM; Wisner KL
Perel JM see Piontek CM; Wisner KL
Perez DE see Sajatovic M
Perkins K see Chengappa KNR
Pettinati HM. Use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. Suppl 20, 26–31
Pettit AR see Pincus HA
Petty RG see Littrell KH
Pfeffer CR. Review of Sameroff AJ, Lewis M, Miller SM (eds): *Handbook of Developmental Psychopathology, 2nd ed.* Oct 832–833
Philipp MK see Silver AA
Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. Sept 721–727
Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. Feb 87–91
Phillips KA see Atiullah N
Phillips ML see Sierra M
Pietzcker A see Jockers-Scherübl MC
Pifarre J see Alonso P
Pileggi TS see Krahn LE
Pincus HA, Pettit AR. Societal costs of chronic major depression. Suppl 6, 5–9
Pinder RM. Introduction. Depression: the relevance of the time factor. Suppl 15, 5–7
Pini S see Ciapparelli A
Pinkerton RC see Clayton AH
Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. Feb 111–113
Pitman RK, Shin LM, Rauch SL. Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. Suppl 17, 47–54
Pitts CD see Tucker P
Pollack MH. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. Suppl 12, 24–29
Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. Suppl 19, 20–25
Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. May 350–357. Correction, Aug 658
Pollock BG see Mulsant BH
Pope HG Jr see Gruber AJ
Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? [commentary] Dec 933–935
Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients [CME]. Feb 135–142
Potkins D see Ballard CG
Preda A, MacLean RW, Mazure CM, Bowers MB Jr. Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Jan 30–33
Preskorn SH see Fava M; Khan AY
Price BH, Baral I, Cosgrove GR, Rauch SL, Nierenberg AA, Jenike MA, Cassem EH. Improvement in severe self-mutilation following limbic leucotomy: a series of 5 consecutive cases. Dec 925–932
Prieto LA see Baptista T
Prieto R see Baca-García E
Pristach CA see Narendran R
Pyne JM, Bullock D, Kaplan RM, Smith TL, Gillin JC, Golshan S, Kelsoe JR, Williams DK. Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. Apr 261–268
Quinn DK see Bogenschutz MP
Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? May 358–361
Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. May 343–346
Rabins PV. Review of Coffey CE, Cummings JL (eds): *The American Psychiatric Press Textbook of Geriatric Neuropsychiatry, 2nd ed.* July 577
Racy JC. Review of Mitchell JE: *Points of View: Stories of Psychopathology.* Dec 997
Rafanelli C see Fava GA
Rahman H see Zeng S
Raimo E see Gillin JC
Rainer MK, Masching AJ, Ertl MG, Kraxberger E, Haushofer M. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. Nov 894–900
Raju JD see Berlin RE
Ralston JP see Hebert AA
Ramírez F see López P
Rapaport M see Patten CA
Rapaport MH. Prevalence, recognition, and treatment of comorbid depression and anxiety. Suppl 24, 6–10
Rapaport MH see Gillin JC
Rapport DJ see Calabrese JR; Wisner KL
Raskin J see Karagianis JL
Rasmussen SA see Phillips KA
Ratzoni G see Bloch Y
Rauch SL see Pitman RK; Price BH
Rausch J see Londborg PD
Rawitt R see Hollander E
Ray JB see Sajatovic M
Ready D see Rothbaum BO
Reddy KP see Andrade C
Reeves KR see Lesem MD
Regan WM. Review of George MS, Belmaker RH (eds): *Transcranial Magnetic Stimulation in Neuropsychiatry.* Mar 210
Reichelt K see Ballard CG
Reimherr FW, Strong RE, Marchant BK, Hedges DW, Wender PH. Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. Suppl 22, 16–23
Reinares M see Colom F; Vieta E
Reus VI. Review of Manji HK, Bowden CL, Belmaker RH (eds): *Bipolar Medications: Mechanisms of Action.* July 576–577
Reynolds CF III see Melhem NM; Mulsant BH
Richards JA see Wozniak J
Richardson GS, Roth T. Future directions in the management of insomnia. Suppl 10, 39–45
Rickels K, Rynn MA. What is generalized anxiety disorder? Suppl 11, 4–12
Rickels K see Ballenger JC
Rico-Villademoros F see Montejo AL
Riemann D see Hajak G
Risby ED. Review of Raphael B, Wilson JP (eds): *Psychological Debriefing: Theory, Practice and Evidence.* Dec 996
Risby ED. Review of Ron MA, David AS (eds): *Disorders of Brain and Mind.* May 377
Rizzo C see Seidman SN

Roback HB. Review of Klein RH, Schermer VL (eds): *Group Psychotherapy for Psychological Trauma.* May 377–378
Robinson M see Phillips KA
Rodenbeck A see Hajak G
Rohrbaugh RM see van Achterberg ME
Romans SE see Elmslie JL
Ronis RJ. Review of Andrews G, Henderson S (eds): *Unmet Need in Psychiatry: Problems, Resources, Responses.* Feb 132–133
Roose SP. Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. Suppl 8, 19–22
Roose SP, Nobler M. ECT and onset of action. Suppl 4, 24–26
Roose SP see Ballenger JC; Leon AC; Seidman SN
Rosales C see Melhem NM
Rosen J see Mulsant BH
Rosen R see Saxena S
Rosenbaum JF. Introduction: early onset of antidepressant action. Suppl 4, 3
Rosenbaum JF see Leon AC
Rossini D see Zanardi R
Roth T. Introduction: new developments for treating sleep disorders. Suppl 10, 3–4
Roth T see Richardson GS
Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD. Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. Aug 617–622
Rothschild AJ. Introduction: sexual dysfunction associated with depression. Suppl 3, 3–4
Roy K see Parker G
Roy-Byrne PP, Clary CM, Miceli RJ, Colucci SV, Xu Y, Grudzinski AN. Effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. Sept 678–682
Roychowdhury SM see Karagianis JL; Kinon BJ
Rubin EH. Review of Reveley MA, Deakin JFW (eds): *The Psychopharmacology of Schizophrenia.* July 577
Rubinow DR see Berlin RE
Ruggiero L see Tucker P
Rummans TA see Krahn LE
Rupprecht R see Zwanzger P
Ruscio AM see Borkovec TD
Rush AJ. Introduction. Chronic major depression: a review and update. Suppl 6, 3–4
Rush AJ. Introduction: management of treatment-resistant depression. Suppl 18, 3
Rush AJ. Introduction: recognizing treatment-resistant depression. Suppl 16, 3–4
Rush AJ see Suppes T; Trivedi MH
Rutgers P see Mitchell PB
Rüther E see Hajak G
Rynn MA see Rickels K
Rytsälä HJ, Melartin TK, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. Record-based analysis of 803 patients treated for depression in psychiatric care [CME]. Sept 701–706
Sable J see Zisook S
Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. Dec 981–984
Sachs GS, Yan LJ, Swann AC, Allen MH. Integration of suicide prevention into outpatient management of bipolar disorder. Suppl 25, 3–11
Sachs GS see Grandin LD; Kupfer DJ
Sackeim HA. Definition and meaning of treatment-resistant depression. Suppl 16, 10–17
Sacristán JA, Gómez JC. Reply to Masand PS: Olanzapine versus other antipsychotics in the treatment of schizophrenia [letter]. Oct 828–829
Saiz-Ruiz J see Baca-García E
Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, Bingham CR. Quetiapine alone and added to a mood stabilizer for serious mood disorders. Sept 728–732
Salgado P see Alonso P
Salinas E see Meoni P; Silverstone PH
Salloum IM see Thase ME
Salomon RM. Review of Weiden PJ, Scheifler PL, Diamond RJ, Ross R: *Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians.* Jan 65
Salzman C. Review of Bennett MJ: *The Empathic Healer: An Endangered Species?* Oct 831–832
Salzman C. Review of Fogel BS, Schiffer RB, Rao SM (eds): *Synopsis of Neuropsychiatry.* Feb 131–132
Salzman C. Review of Iversen LL: *The Science of Marijuana.* Aug 661–662
Salzman C. Review of Kennedy GJ: *Geriatric Mental Health Care: A Treatment Guide for Health Professionals.* Sept 737–738
Salzman C, Goldenberg I, Bruce SE, Keller MB. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown Anxiety Disorders Research Program. Mar 149–152
Salzman C see Silvestri R
Sambamoorthi U see Walkup J
Samellas D see Bhandari S
Sanberg PR see Silver AA
Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Apr 273–281
Sanz-Carrillo C see García-Campayo J
Sartorius N. Economic and social burden of depression. Suppl 15, 8–11
Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, Bystritsky A. Retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder [CME]. Jan 67–72
Schaefer M see Grunze HCR
Schatzberg AF. Reply to: Lara DR. Should we keep calling antidepressants *antidepressants*? [letter] Oct 829–830
Schausberger B see Marténvi F
Schloesser S see Grunze HCR
Schmidt PJ see Berlin RE
Schneider RK see Kornstein SG
Schneidman M see Dossenbach MRK
Schneier FR. Treatment of social phobia with antidepressants. Suppl 1, 43–48
Schneier FR, Barnes LF, Albert SM, Louis ED. Characteristics of social phobia among persons with essential tremor. May 367–372
Schnierow B see Gillin JC
Scholten DJ see Malla AK
Schooler NR. Statistical comparison of clinical trials. Suppl 9, 35–37
Schüle C see Zwanzger P
Schwab JJ. Review of Mitchell JE, Crosby RD, Wonderlich SA, Adson DE: *Elements of Clinical Research in Psychiatry.* Aug 659
Seaburg H see Van Meter SA
Seedat S, Stein DJ, Harvey BH. Inositol in the treatment of trichotillomania and compulsive skin picking [letter]. Jan 60–61
Seger A, Lamberti JS. Priapism associated with polypharmacy [letter]. Feb 128
Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. June 406–412
Senior C see Sierra M
Seno H see Miyaoka T
Serretti A see Zanardi R
Shah VN see Nelson EB
Shahab H see Janson MP
Shalev AY. What is posttraumatic stress disorder? Suppl 17, 4–10
Shalev AY see Agid O
Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy [letter]. Mar 205–206
Shear MK see Melhem NM
Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. Suppl 19, 26–31
Sheffield D see Sheps DS
Shelton MD see Calabrese JR
Shelton RC. Introduction: remission of anxiety-related disorders. Suppl 12, 3–4
Shelton RC, Brown LL. Mechanisms of action in the treatment of anxiety. Suppl 12, 10–15
Sheps DS, Sheffield D. Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. Suppl 8, 12–16
Sheps DS see Ballenger JC
Shi Q see Budman CL
Shin LM see Pitman RK
Shirley ER see Calabrese JR
Shon SP see Suppes T
Shrivastava RK see Ferguson JM
Shuchter SR see Zisook S
Shyovitz M. Family member's legal experience with an insurer's refusal to recertify inpatient mental health treatment. Suppl 25, 44–50
Shytle D see Silver AA
Sierra M, Phillips ML, Lambert MV, Senior C, David AS, Krystal JH. Lamotrigine in the treatment of depersonalization disorder [letter]. Oct 826–827
Siever LJ see Hollander E
Silver AA, Shytle D, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. Sept 707–714
Silverstone JT see Elmslie JL

Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. July 523–529
Silvestri R, Pace-Schott EF, Gersh T, Stickgold R, Salzman C, Hobson JA. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. Aug 642–652
Simpson GM see Currier GW; Kingsbury SJ
Simpson JSA see Kaplan BJ
Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. Sept 694–700
Singer TM see Goldberg JF
Singleton SS. Depression and quality of life: a patient's perspective. Suppl 26, 22
Siniscalchi JM see Phillips KA
Slaughter JR. Review of Lauterbach EC (ed): *Psychiatric Management in Neurological Disease, 1st ed.* June 483–484
Smith RC see Lindenmayer J-P
Smith TL see Pyne JM
Smith-Vaniz A see Gillin JC
Söderberg S see Hägg S
Sokero TP see Rytsälä HJ
Solomon RM. Review of Mallick BN, Inoué S (eds): *Rapid Eye Movement Sleep.* May 378
Solomon Z. Impact of posttraumatic stress disorder in military situations. Suppl 17, 11–15
Sonawalla SB. Citalopram in the maintenance treatment of major depressive disorder [letter]. Dec 993
Sorbara F see Henry C
Southwick SM see van Achterberg ME
Souza DO see Lara DR
Spatz E see Seidman SN
Srihari BS see Andrade C
Stahl SM. Does evidence from clinical trials in psychopharmacology apply in clinical practice? [Brainstorms] Jan 6–7
Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 1: "Goldilocks" actions at dopamine receptors [Brainstorms]. Nov 841–842
Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 2: illustrating their mechanism of action [Brainstorms]. Dec 923–924
Stahl SM. Effects of estrogen on the central nervous system [Brainstorms]. May 317–318
Stahl SM. Fibromyalgia: the enigma and the stigma [Brainstorms]. July 501–502
Stahl SM. Gut feelings about irritable bowel syndrome [Brainstorms]. Aug 590–591
Stahl SM. "Hit-and-run" actions at dopamine receptors, pt 1: mechanism of action of atypical antipsychotics [Brainstorms]. Sept 670–671
Stahl SM. "Hit-and-run" actions at dopamine receptors, pt 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics [Brainstorms]. Oct 747–748
Stahl SM. Natural estrogen as an antidepressant for women [Brainstorms]. June 404–405
Stahl SM. Psychopharmacology of sex, pt 1: neurotransmitters and the 3 phases of the human sexual response [Brainstorms]. Feb 80–81
Stahl SM. Psychopharmacology of sex, pt 2: effects of drugs and disease on the 3 phases of human sexual response [Brainstorms]. Mar 147–148
Stahl SM. Why drugs and hormones may interact in psychiatric disorders [Brainstorms]. Apr 225–226
Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. Suppl 4, 17–23
Stahl SM see Ferguson JM; Leon AC
Stanley B see Pearson JL
Stein DJ. Comorbidity in generalized anxiety disorder: impact and implications. Suppl 11, 29–34
Stein DJ see Ballenger JC; Hollander E; Seedat S
Stein MB see Gillin JC; Lang AJ
Steinmann AF see Parris C
Sterr A see Grunze HCR
Stickgold R see Silvestri R
Street GP see Foa EB
Street JS see Clark WS
Streltzer J. Review of Wall PD, Melzack R (eds): *Textbook of Pain, 4th ed.* Aug 660
Strong RE see Reimherr FW
Strous RD see Chelben J
Strunjas SS see Janson MP
Strupinsky S see Bloch Y
Su JM see Zhang XY
Sullivan KA see Caroff SN
Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, Toprac MG, Rush AJ, Shon SP, Altshuler KZ. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. June 439–447
Suppes T see Calabrese JR
Sussman N. Introduction: weight gain and glucose regulation during antipsychotic drug treatment. Suppl 23, 3–4
Sussman N. Review of atypical antipsychotics and weight gain. Suppl 23, 5–12
Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor– and imipramine-controlled trials. Apr 256–260
Suzuki H see Wada K
Swann AC. Major system toxicities and side effects of anticonvulsants. Suppl 14, 16–21
Swann AC see Sachs GS; Suppes T
Swann AG see Ballard CG
Sweet RA see Mulsant BH
Swift RH see Lesem MD
Syvälahti EK see Appelberg BG
Szymanski KA see Basson BR
Tachibana H see Miyaoka T
Tajima O. Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Suppl 13, 39–44
Tajima O see Ballenger JC
Tam EM see Lam RW
Tamminga CA. Introduction: evaluating clinical trial data from schizophrenia research. Suppl 9, 3–4
Tarlow G see Saxena S
Taylor BP see Quitkin FM
Taylor CC see Basson BR; Jones B
Temlett JA see Bruggeman R
Terao T. Lithium therapy for corticosteroid-induced mood disorder [letter with reply]. Jan 57
Thakur A see Karagianis JL
Thase ME. Methodology to measure onset of action. Suppl 15, 18–21
Thase ME. Need for clinically relevant research on treatment-resistant depression [commentary]. Apr 221–224
Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. Sept 683–687
Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. Suppl 18, 18–24
Thase ME, Nierenberg AA, Keller MB, Panagides J, for the Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Oct 782–788
Thase ME, Salloum IM, Cornelius JD. Comorbid alcoholism and depression: treatment issues. Suppl 20, 32–41
Thase ME see Entsuah AR
Thompson P see Ballard CG
Tietjen J see Parris C
Todd C see O'Leary D
Tohen MF see Sanger TM
Tollefson GD see Basson BR; Dossenbach MRK; Kinon BJ
Tondo L, Ghiani C, Albert M. Pharmacologic interventions in suicide prevention. Suppl 25, 51–55
Toney GB see Lam YWF
Toprac MG see Suppes T
Torrent C see Vieta E
Torres L see Alonso P
Trivedi MH. Sensitizing clinicians and patients to the social and functional aspects of remission. Suppl 19, 32–35
Trivedi MH, Baker SM. Clinical significance of monitoring early symptom change to predict outcome. Suppl 4, 27–33
Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. Suppl 6, 22–29
Trivedi MH, Kleiber BA. Using treatment algorithms for the effective management of treatment-resistant depression. Suppl 18, 25–29
Trivedi MH, Rush AJ, Carmody TJ, Donahue RMJ, Bolden-Watson C, Houser TL, Metz A. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Oct 776–781
Trivedi MH, Rush AJ, Pan J-Y, Carmody TJ. Which depressed patients respond to nefazodone and when? 158–163
Trivedi MH see Fava M; Leon AC
Trufasiu D see Kingsbury SJ
Tsubouchi K see Miyaoka T
Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Nov 860–868
Tundo A see Ciapparelli A
Tune LE. Anticholinergic effects of medication in elderly patients. Suppl 21, 11–14

Tune LE. Risperidone for the treatment of behavioral and psychological symptoms of dementia. Suppl 21, 29–32
Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia [CME]. July 545–551
Valenti AM see Narendran R
Vallejo J see Alonso P
van Achterberg ME, Rohrbaugh RM, Southwick SM. Emergence of PTSD in trauma survivors with dementia [letter]. Mar 206–207
van der Gaag RJ see Buitelaar JK
van der Linden C see Bruggeman R
van Gils K see Kooij JJS
van Harten PN see de Groot IW
Van Meter SA, Seaburg H, McLendon B, Doraiswamy PM. Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose [letter]. Dec 993–994
Vapnik T see Saxena S
Vardulaki K see O'Leary D
Vemulapalli HK see Chengappa KNR
Verduin ML see Shapira NA
Vieta E, Colom F, Martínez-Arán A, Reinares M, Benabarre A, Corbella B, Gastó C. Reboxetine-induced hypomania [letter]. Aug 655–656
Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martínez G, Fernández A, Colom F, Martínez-Arán A, Torrent C, for the Group for the Study of Risperidone in Affective Disorders (GSRAD). Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Oct 818–825
Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M, for the Group for the Study of Risperidone in Affective Disorders (GSRAD). Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Aug 623–630
Vieta E see Colom F; Navarro V
Viguera AC see Cohen LS
Visnic S see Valenstein M
Voderholzer U see Hajak G
Volavka J see Citrome L
Volpicelli JR. Alcohol abuse and alcoholism: an overview. Suppl 20, 4–10
Wada K, Yamada N, Suzuki H, Lee Y, Kuroda S. Reply to Terao T: Lithium therapy for corticosteroid-induced mood disorder [letter]. Jan 57–58
Wahlbeck K see Ahokas A
Walbek NH see Kluznik JC
Walden J see Grunze HCR
Waldinger MD, Olivier B. Sexual dysfunction and fluvoxamine therapy [letter with reply]. Feb 126–127
Walker DJ see Jones B
Walker JB, Klein RM, Yee S-L. Type II error and antidepressants [letter with reply]. May 373–374
Walkup J, Sambamoorthi U, Crystal S. Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia. Mar 174–178
Walsh BT see Simpson MM
Walther A see Zwanzger P
Weber B see Lederbogen F
Weiden PJ see Grunebaum MF
Weihs KL, Batey SR, Houser TL, Donahue RMJ, Ascher JA. Reply to Walker JB: Type II error and antidepressants [letter]. May 374–375
Weinstein DD. Review of Piasecki M, Newhouse PA (eds): *Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics.* June 483
Weisæth L. Acute posttraumatic stress: nonacceptance of early intervention. Suppl 17, 35–40
Weizman A see Aizenberg D
Welge JA see Nelson EB
Wells LA. Review of Coles R (ed): *The Erik Erikson Reader.* July 576
Wender PH see Reimherr FW
Wilhelm K see Gladstone GL; Mitchell PB; Parker G
Wilkinson BJ see Silver AA
Williams DK see Pyne JM
Williams R. Optimal dosing with risperidone: updated recommendations. Apr 282–289
Williams SM see Elmslie JL
Wingrove J see Critchlow DG
Winkelman JW. Schizophrenia, obesity, and obstructive sleep apnea. Jan 8–11
Winograd A see Saxena S
Wirshing DA. Adverse effects of atypical antipsychotics. Suppl 21, 7–10
Wirshing WC. Movement disorders associated with neuroleptic treatment. Suppl 21, 15–18
Wirshing WC see De Deyn
Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. Feb 82–86
Wisner KL see Piontek CM
Wittchen H-U. Introduction. Optimizing outcomes of treating depression: meeting patient expectations. Suppl 26, 3–4
Wittchen H-U, Holsboer F, Jacobi F. Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. Suppl 26, 23–28
Wittchen H-U, Hoyer J. Generalized anxiety disorder: nature and course. Suppl 11, 15–19
Wittchen H-U see Ballenger JC
Wolter TD see Patten CA
Wood JS see Connor DF
Wozniak J, Biederman J, Richards JA. Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. Suppl 14, 10–15
Wu GY see Zhang XY
Xu Y see Roy-Byrne PP
Yamada N see Wada K
Yamamori C see Miyaoka T
Yan LJ see Grandin LD; Sachs GS
Yatham LN see Lam RW; Miller DS
Yee S-L see Walker JB
Yehuda R. Biology of posttraumatic stress disorder. Suppl 17, 41–46
Yehuda R. Introduction. Understanding posttraumatic stress disorder (PTSD): an overview. Suppl 17, 3
Yehuda R see Tucker P
Young CM see Narendran R
Yule W. Posttraumatic stress disorder in the general population and in children. Suppl 17, 23–28
Zada J see Kingsbury SJ
Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. Suppl 3, 35–43
Zajecka JM see Fava M; Lesem MD
Zanardi R, Rossini D, Serretti A. Reply to Kumar S: Problems with ensuring a double blind [letter]. Apr 296
Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Nov 849–854
Zaninelli R see Pollack MH; Tucker P
Zeng S, Kim CH, Rahman H. Psychotic symptoms presented in familial Creutzfeldt-Jakob disease, subtype E200K [letter]. Sept 734–735
Zhang PY see Zhang XY
Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. Double-blind, placebo-controlled trial of extract of *Ginkgo biloba* added to haloperidol in treatment-resistant patients with schizophrenia. Nov 878–883
Zhou DF see Zhang XY
Zimmerman M see Posternak MA
Zirul S see Malla AK
Zisook S, Shuchter SR, Pedrelli P, Sable J, Deaciuc SC. Bupropion sustained release for bereavement: results of an open trial. Apr 227–230
Zisook S see Gillin JC; Jin H
Zorn SH see Casey DE
Zubenko GS see Mulsant BH
Zwanzger P, Baghai TC, Schüle C, Minov C, Padberg F, Möller H-J, Rupprecht R. Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. Aug 656–657
Zwanzger P, Marcuse A, Boerner RJ, Walther A, Rupprecht R. Lithium intoxication after administration of AT_1 blockers [letter]. Mar 208–209